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G-substrate is a 23 kDa protein named as a specific substrate of cGMP-dependent 
protein kinase and found predominantly in cerebellar Purkinje cells. As a component 
of the NO/cGMP/PKG pathway, G-substrate is potentially involved in several 
important cellular processes and has so far been associated with a number of disease 
conditions: a single point mutation in G-substrate has been linked to 
hypercholesterolaemia, while the potent inhibition of PP2A by phosphorylated G-
substrate possibly influences Tau protein hyperphosphorylation and contributes to 
Alzheimer‟s disease pathology. Conversely, overexpression of G-substrate protein in 
dopaminergic neurons has been found to protect neurons from Parkinson‟s disease 
toxins, making G-substrate a possible target of interventions for mitigating the 
debilitating effects of Parkinson‟s disease on patients. 
A shorter splice variant, which only retains one of the phosphorylatable threonine 
motifs, has recently been described for G-substrate and given the importance of 
phosphorylation to its action as a phosphatase inhibitor, this study focuses on 
determining whether both variants of the protein exhibit similar levels of phosphatase 
inhibition and interact with the same/similar proteins in vivo. We were also interested 
in determining whether the 51 amino acid section absent from short G-substrate 
resulted in any significant differences in protein structure, which potentially has 
implications on functions in vivo. 
My results indicate the association of G-substrate with a wide range of proteins 
involved in processes including cell cycle regulation, endocytosis and signalling and 
the two variants do not always interact with the same proteins. Among these 
interactors is the PARK 7/ DJ-1 protease, which like G-substrate has been shown to 
be neuroprotective. I have found that G-substrate is proteolysed by DJ-1 in its active 
form and interactions between these two proteins is affected by the anti-vertigo drug 
Tanganil. Phosphatase inhibition studies suggest that the G-substrate variants affect 
phosphatase activity to different extents under similar conditions, while NMR and 
circular dichroism structural studies suggest that in solution, the full length G-
substrate variant is slightly more compactly folded. 
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Understanding the details of G-substrate action in the cell will lead to a better 
understanding of its roles including the protection of dopaminergic neurons from 
Parkinson‟s disease toxins and shed more light on the intricacies of the 
NO/cGMP/PKG signalling pathway as a whole, thus providing important 
information that might help improve strategies for dealing with conditions involving 
this pathway and help develop interventions for diseases such as Alzheimer‟s and 
Parkinson‟s. 
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Chapter 1: Introduction 
1.1 G-substrate 
Human G-substrate, an acid and heat stable protein (1) also known as protein 
phosphatase 1 regulatory subunit 17 (C7 orf 16), is located in the 7p15 region of 
chromosome 7(2). The G-substrate gene (Ensembl ID: ENSG00000106341.6) 
encodes three transcripts; PPP1R17-001, PPP1R17-002 and PPP1R17-003 (Error! 
eference source not found.). PPP1R17-003 encodes a processed transcript with no 
known protein product while the other two transcripts are protein coding. PPP1R17-
001 codes for isoform 1 of the protein, which is 155 amino acids long. The protein 
coded for by PPP1R17-002 is a 104 amino acid protein, with identical N- and C-
termini to isoform 1, but missing a 51 amino acid section containing the first 
phosphorylation motif of full length G-substrate (Figure 1.2). Phosphorylation of the 
threonine residue retained in the short isoform was found by Aitken and coworkers to 
be essential for the phosphatase inhibition activity of full length G-substrate (3) The 
G-substrate gene is conserved across several species, with protein sequences from 
human, chimpanzee, rat, mouse and chicken showing large areas of homology with 
almost complete identity at the phosphorylation motifs (Figure 1.3).  
Online subcellular localization prediction using WoLF PSORT (4) revealed the 
existence of a possible endoplasmic reticulum (ER) membrane retention signal – a 
„KKXX-like‟ motif represented by the sequence DKIA in the C-terminal region and 
one of two peroxisomal targeting signal (PTS2) of the consensus (R/K)-(L/I/V)-X5-
(Q/H)-(L/I/V),within the sequence KLDPRCSHL located near the N-terminal region 
of both full length and short G-substrate. The presence of these signals suggests that 
in vivo, some G-substrate protein might exist localized to the ER, suggesting a role in 
either fatty acid or protein synthesis depending on whether localization is to the 
smooth or rough ER. The additional presence of a peroxisomal targeting sequence, 
however, might indicate that G-substrate is localized to the smooth rather than the 
rough ER. Peroxisomes, which are thought to originate from the ER (5), represent a 
class of ubiquitous and essential cell organelles characterized by the presence of a 
proteinaceous matrix surrounded by a single membrane and are involved in fatty acid 
(FA) beta-oxidation in virtually all organisms. Peroxisomes of higher eukaryotes are, 
in addition, involved in a number of functions not shared by peroxisomes in lower 
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eukaryotes, including ether phospholipid biosynthesis, FA alpha-oxidation, and 
glyoxylate detoxification. 
Defects in peroxisomal biogenesis or protein recruitment have been linked with a 
number of diseases including Zellweger spectrum disorders, X-linked 
adrenoleukodystrophy (X-ALD) and Refsum disease (phytanoyl-CoA hydroxylase 
deficiency) (6). 
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Figure 1.1: Ensembl image showing transcripts of the G-substrate gene.  
A and B represent translated mRNA transcripts for G-substrate variants 1 and 2 respectively, while C represents an untranslated transcript of the G-substrate gene 
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Figure 1.2: Alignment of human G-substrate isoforms. 
The phosphorylation motif is underlined, T represents phosphorylatable threonine residues, residues in 
red flank area deleted from the full length protein, 1=full length G-substrate and 2=short G-substrate 
 
 
Figure 1.3: Alignment of canonical G-substrate sequences from mouse, rat, human, chimpanzee, 
cow and chicken. 
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1.1.1 Discovery of G-substrate 
G-substrate was discovered during an investigation to identify endogenous substrates 
of cyclic guanosine monophosphate (cGMP)-dependent protein kinase (cGK) in 
mammalian brain. It was discovered that G-substrate, a soluble protein with an 
apparent molecular weight of 23,000 from rabbit cerebellum, was rapidly 
phosphorylated by cGK, while the presence of types I and II cyclic adenosine 
monophosphate (cAMP)-dependent protein kinases (PKA) failed to significantly 
increase the amount of phosphate incorporated into the protein (1). 
 
1.1.2 G-substrate Localization 
G-substrate contains three clusters of basic amino acids ---KKKPR/IKGK---
KKPRRKDT(Pi)PA---KKPRRKDT(Pi)PA---, the second and third of which 
possess identical amino acid sequences and occur adjacent to the phosphorylatable 
threonine residues originally described by Aitken and co-workers through direct 
protein sequencing of G-substrate purified from rabbit cerebellum [3]. Although no 
specific function has been determined for these amino acid clusters, it has been 
suggested that these clusters could represent potential nuclear localization signals 
(NLSs), which are characterized by clusters of basic amino acids. It is also possible 
that the presence of a number of hydrophobic amino acids interspersed in short 
sequences might represent a nuclear export sequence (NES).The presence of both 
NLSs and NESs (Figure 1.4) suggests that G-substrate may shuttle between the 
cytoplasm and the nucleus, a possibility supported by the observation that studies of 
cerebellar Purkinje cells in brain slices show G-substrate in both the cytosol and the 
nucleus of the Purkinje cells. The location of NLSs near the phosphorylation sites of 
G-substrate could result in the phosphorylation state of the protein determining the 
location of the protein; it is likely that upon phosphorylation, the negative charge 
introduced by the PO4
2-
 group might disrupt the structure of the amino acid clusters, 
interfering with their ability to bind to shuttling proteins and resulting in the retention 
of phosphorylated G-substrate either in the nucleus or in the cytoplasm. 
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Figure 1.4: Alignment of human G-substrate isoforms showing positions of NESs and NLSs. 
Blue and green lines show amino acids making up respective signals, T represents phosphorylatable 
threonine residues, 1=full length G-substrate and 2=short G-substrate 
 
While several regions of rabbit brain including the hippocampus, caudate and 
cerebral cortex were investigated by Schlichter and coworkers in 1978, the 23,000 
molecular weight band representing G-substrate was only found in the cerebellar 
fractions (7). Endo and co-workers later confirmed that G-substrate was localized 
almost exclusively to the Purkinje cells of the cerebellum (8). Low levels of G-
substrate have also been detected in the paraventricular region of the hypothalamus 
and the pons/medulla (9). A small proportion of G-substrate has also been found to 
co-express with other signalling components of the NO-cGMP-cGK pathway in the 
retinas of adult mice and rats, where it is located in a subpopulation of amacrine cells 
and in C38-positive retinal ganglion cells (RGCs), but not in alpha RGC‟s (10). 
 
 
1.1.2.1 The Cerebellum 
The cerebellum is located beneath the cerebrum and behind the brain stem (Figure 
1.5) and accounts for approximately 10 % of the volume of the brain (11). Despite its 
relatively small size, the cerebellum is thought to contain over half the total number 
of neurons in the brain (12). 
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Figure 1.5: A lateral view of the human brain showing its main features 
 
The cerebellum possesses three major functional divisions  (Figure 1.6): the 
spinocerebellum, in the vermis and intermediate part of the cerebellar hemispheres is 
involved in ongoing maintenance of tone, execution, and control of axial and 
proximal (vermis) and distal movements; the cerebrocerebellum, in the lateral part of 
the hemisphere is involved in initiation, motor planning, and timing of coordinated 
movements (13); and the vestibulocerebellum in the flocculonodular lobe is involved 
in axial control and balance and positional reflexes. The NO/cGMP/PKG pathway, of 
which G-substrate is a member has been shown to be essential in the induction of 
cerebellar long term depression (LTD) (14) and LTD-dependent motor learning. This 
includes the vestibule-ocular reflex adaptation controlled by this part of the 
cerebellum.  In addition, we have evidence that the drug Tanganil, affects the 
interaction between the Parkinson‟s disease protein, Park7/DJ-1 and G-substrate (see 
section 7.4.2). Tanganil has been shown to target the vestibular system (15). 
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Figure 1.6: Flattened view of the cerebellar surface illustrating the three major subdivisions 
(16). 
 
The cerebellar cortex is divided into three distinct cellular layers with specific 
cellular composition (Figure 1.7).  The molecular layer is the outermost layer and is 
primarily made up of Purkinje cell dendrites and granule cell axons (parallel fibres).  
The molecular layer also contains the stellate and basket cell interneurons (17). Next 
is the Purkinje cell layer, which is mainly made up of a monolayer of Purkinje cell 
somata. The Purkinje cell layer also contains the cell bodies of Candelabrum cells 
and Bergmann Glia (18). Lastly, bordering the medullary centre of the cerebellum is 
the granular (granule cell) layer. The small granule cells comprise the great majority 
of this layer within which the somata of the Golgi cell, Lugaro cell interneurons and 
the unipolar brush cells are also located. 
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Figure 1.7: The Three Cellular Layers of the Cerebellar Cortex (18). 
 
Purkinje cells form the sole output of the cerebellar cortex (19) and are consequently 
extremely important for the function and development of the cerebellum. Diseases 
and disorders affecting the function of Purkinje cells result in severe sensory-motor 
defects such as ataxia, altered motor learning, and possibly cognitive defects (20). As 
mentioned in section 1.1.2 above, the majority of G-substrate is located in the 
Purkinje cells, where it is found in the dendrites, somata and axons, suggesting an 
important role for this protein in Purkinje cell and ultimately cerebellar function. 
 
1.1.2.2 G-substrate Expression is Age-dependent 
In 2002 Iida and coworkers, using a fluorescence differential display PCR method, 
identified G-substrate as one of five genes expressed in an age-dependent manner in 
the brains of 3-day- to 15-month-old mice (21). Quantitative PCR analyses revealed 
that the expression of G-substrate mRNA was quite low in the brains of 3-day- and 
1-week-old mice, but was modest in 2-week- to 9-month-old mice. The highest 
expression of G-substrate was observed in 15-month-old mice, which had mRNA 
levels approximately twice that of 6- and 9-month-old mice. The notable increase in 
G-substrate expression in the brains of 2-week-old mice corresponds to the 
maturation of cerebellar neuronal circuitry (22-24), including the maturation of the 
cerebellar Purkinje cells where G-substrate is most abundant. This age-dependent 
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increase in G-substrate expression suggests the possibility of G-substrate 
contributing physiologically to mechanisms that might compensate for the age-
dependent decline in motor function (25,26), since the cerebellum plays an important 
role in controlling motor function. 
 
1.1.3 G-substrate Polymorphisms 
Natural variations in amino acid composition occur at positions 10 (R to L) and 12 
(V to L) (27). One single nucleotide polymorphism (SNP), involving the substitution 
of a tyrosine residue with a cytosine residue in the 5‟ promoter region of the G-
substrate gene (–1323T>C), has been linked to hypercholesterolemia in subjects 
studied in East-Central Japan. The T-allele was found to result in 
hypercholesterolemia approximately two-fold higher than in individuals lacking the 
T-allele with individuals carrying the T-allele showing total cholesterol levels 
approximately 14 % higher than those without it (28). 
 
1.1.4 Phosphorylation of G-substrate 
G-substrate is phosphorylated exclusively on two threonine residues (Thr 68 – site 1 
and Thr 119 – site 2 in humans) successfully by both cyclic AMP- and cyclic MP-
dependent protein kinases (29). These serine/threonine protein kinases are very much 
alike, showing highly similar amino acid compositions and hydrodynamic shapes 
among other things. PKA and cGK also share a number of in vitro substrates 
including glycogen synthase, pyruvate kinase and cardiac troponin–1 with the in 
vitro phosphorylation of such shared substrates generally proceeding more rapidly 
with PKA. In spite of their similarities, these two kinases also exhibit several major 
differences, which support suggestions that they regulate distinct physiological 
processes. These include their sensitivities to and mechanisms of activation by cyclic 
nucleotides, immunochemical cross-reactivity, and tissue distributions among others. 
Perhaps the most significant difference between these kinases is the fact that all the 
functional domains of cGK are found on a single polypeptide chain, whereas PKA 
has separate regulatory (cAMP binding) and catalytic chains. 
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1.1.4.1 Cyclic GMP-dependent Protein Kinase 
G-substrate was discovered and named as a specific substrate of cGK. Mammalian 
cGK exists as three isoforms encoded on two genes. Human PRKG1, located on 
chromosome 10, encodes the soluble isoform I of cGK. The amino terminus (first 90 
to 100 residues) of cGK I is encoded by two alternative exons, producing cGK 
isoforms Iα and Iβ. cGK I has been found at high concentrations in all types of 
smooth muscle, hippocampal neurons, the lateral amygdala, platelets and cerebellar 
Purkinje cells (30) and is most likely the isoform with which cerebellar G-substrate 
interacts. PRKG2 is located on chromosome 4 and encodes the membrane-bound 
isoform 2 (cGK II), which is expressed in prostate, small intestine, colon, thymus and 
prostate. cGK phosphorylates both sites of G-substrate at similar rates, yielding a 
Vmax of 2.2 µmol/min/mg and a Km of 0.21µM. The high degree of specificity 
exhibited by cGK towards G-substrate is purported to be a result of selective 
substrate binding rather than catalytic efficacy (29).The two isoforms of cGK exist as 
homodimers, held together by leucine zippers in the N-terminus and have similar 
domain structures made up of an N-terminal regulatory domain containing a 
dimerization and an autoinhibitory region, two tandem cGMP-binding domains and a 
C-terminal catalytic domain (Figure 1.8).  
 
 
Figure 1.8: A schematic representation of the functional domain structure of a monomer of 
cGK. 
„N‟ and „C‟ refer to the N- and C-termini respectively. „Dimer‟ represents the dimerization domain 
and „A-I‟ represents the autoinhibitory domain. Numbers indicate amino acid residues in the 
polypeptide chain.  
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In the absence of cGMP, cGKs exist in a conformation which has their 
catalytic/substrate binding domains bound to an autoinhibitory/ pseudo substrate 
domain, making them unable to bind substrates and effect catalysis (Figure 1.9). 
Upon cGMP binding, the apo-enzyme structure effectively unfurls and frees the 
catalytic domain for substrate phosphorylation (31). Research has shown that the two 
cGMP-binding sites contribute differently to activation of cGK I and cGK II. 
Binding of cGMP to the high affinity sites alone was found to result in partial 
activation of cGK I kinase activity, which was further activated upon binding of high 
concentrations of cGMP to its low affinity sites. In cGK II, occupation of the high 
affinity site had no effect on the kinase‟s ability to phosphorylate its targets, 
implying that occupation of the low affinity cGMP-binding site was required for 
effective activation of cGK I. 
 
 
Figure 1.9: An illustration of mode of activation of cGK by cGMP. 
Image is adapted from Taylor et al. (32). The kinase is shown as a monomer for simplicity. 
  
1.1.4.2 Cyclic AMP-dependent Protein Kinase 
Although G-substrate is successfully phosphorylated by both cGK and cAK, 
phosphorylation by cAK occurs at a much lower rate, yielding a Vmax of 2.3 
pmol/min/mg and a Km of 5.8 µM. Furthermore, unlike cGK, cAK phosphorylates 
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the two threonine residues of G-substrate at different rates, with site 2 being 
phosphorylated 4 times more slowly than site 1(3). cAK occurs naturally as a 
quaternary structure made up of two regulatory (R) and two catalytic (C) subunits. R 
subunits exist as two major forms, R I and R II, each of which has two subtypes, 
alpha and beta. All four subtypes of the cAK regulatory subunit are encoded by 
different genes. The catalytic subunit exists as three isoforms, alpha, beta and 
gamma, encoded on chromosomes 19, 1 and 9 respectively. The different isotypes of 
cAK subunits are believed to facilitate targeting to tissues and cells. Regulatory 
subunits contain two cAMP binding domains, an auto inhibitory domain and a 
dimerization domain at the N-terminal position. A typical catalytic subunit contains 
and ATP binding site, a site at which the regulatory subunit binds and the active site 
of the enzyme (Figure 1.10). Interestingly, although cGK and cAK have a number of 
substrates in common, the positions of the high and low affinity cyclic nucleotide 
binding sites, which are vital to their activation, are reversed in these two kinases. 
 
 
Figure 1.10: A schematic representation of typical domain architecture of cAK regulatory and 
catalytic subunits. 
„N‟ and „C‟ refer to the N- and C-termini respectively and „A-I‟ represents the autoinhibitory domain. 
 
The cAK holoenzyme exists as a „dimer of dimers‟ – each dimer consists of a 
catalytic subunit bound to a regulatory subunit and the two dimers interact at their 
dimerization domains to form a tetrad, the inactive cAK enzyme. Upon cAMP 
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binding, the catalytic subunits dissociate from the regulatory subunits, free and active 
and able to phosphorylate its substrates (Figure 1.11). 
 
Figure 1.11: An illustration of cAK activation by cAMP. 
 
1.1.5 Phosphatase Inhibition by Phospho G-substrate 
Phospho-G-substrate is known to effectively inhibit protein phosphatase 1 (PP1) and 
protein phosphatase 2A (PP2A) upon phosphorylation at two threonine residues. PP1 
and PP2A have been found to catalyze about 90 % of the phospho-protein 
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dephosphorylations that occur in the eukaryotic cell. Mammals are thought to contain 
as many as 650 distinct PP1 complexes and approximately 70 PP2A holoenzymes 
(33), suggesting that PP1 catalyzes the majority of protein dephosphorylation events 
in the mammalian cell. Work done by Hall and coworkers (9) and by Endo and 
coworkers (8) suggest that phospho-G-substrate inhibits one of these phosphatases 
more effectively than the other. These investigations were, however, carried out 
under different conditions with Endo and coworkers using PP2Ac to assay the 
protein phosphatase inhibitory activities of human and rat G-substrate while Hall and 
coworkers used PP2A1 to assay the protein phosphatase inhibitory activity of mouse 
G-substrate. It is therefore also probable that the differences observed could be due 
to the unique effects of the different conditions used by the two groups on the 
reaction dynamics. Further investigation is therefore necessary to confirm the 
existence of any differences in the ability of G-substrate to inhibit these phosphatases 
and to determine whether G-substrate protein purified from different species affect 
these and other phosphatases differently. 
 
1.1.5.1 Protein Phosphatase 1 
PP1 plays important roles in the control of glycogen metabolism, muscle contraction, 
cell progression, neuronal activities, RNA splicing, mitosis, apoptosis, protein 
synthesis, and the regulation of membrane receptors and channels (34) The human 
genome, like other mammalian genomes, contains three PP1-encoding genes. These 
genes encode four different catalytic subunits: PP1α, located on chromosome 11, 
PP1β, also known as PP1δ, which is located on chromosome 2 and the splice variants 
PP1γ1 and PP1γ2 located on chromosome 12. These isoforms of PP1c are thought to 
have about 85 % similarity, differing mainly in their N- and C-termini and exhibiting 
a similarly broad substrate similarity as free PP1 isoforms. The targeting of the PP1 
catalytic subunit to particular cellular locations and its specificity towards its wide 
range of targets has been shown to result mainly from interactions with a large 
number of regulatory subunits including activity modulators, chaperones and 
inhibitors (35). A number of docking/interacting motifs/domains have been described 
for PP1 interactions with regulatory proteins.  
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The primary motif, referred to as the RVxF domain, generally conforms with the 
consensus sequence K/R K/R V/I x F/W, where x is any residue other than 
phenylalanine, isoleucine, methionine, tyrosine, aspartic acid, or proline (36). This 
sequence is thought to bind in an extended conformation to a PP1 hydrophobic 
groove about 20 Å (~ 2.1 nm) away from the active site and function mainly to 
anchor interacting proteins to PP1. This brings PP1 close to its interacting proteins 
and promotes secondary interactions that contribute to PP1 isoform selection, 
determination of activity and substrate specificity of the holoenzyme.  
Other interacting/docking domains currently identified include the ΦΦ pocket 
described for interactions with the RNA-binding protein nuclear inhibitor of PP1 
(NIPP1) (37). This hydrophobic pocket is formed by PP1 residues Leu75, Tyr78, 
Met282, Ile295, Leu296, and Lys297 and regulatory proteins access via two sequential 
hydrophobic (ΦΦ) residues, Ile209 and Ile210 of NIPP1. A similar but not identical 
interaction with PP1 has been observed involving residues Val458 and Phe459 of 
spinophilin, an actin-binding PP1 regulator highly enriched in dendritic spines.  
The SILK motif, which contains the consensus sequence G/S I L R/K has been found 
in seven of the vertebrate PP1 interactors currently identified. This motif is usually 
positioned N-terminal to the RVxF sequence and like the RVxF domain, does not 
affect the conformation of the PP1 enzyme, but contributes to the effective anchoring 
of PP1 to interacting proteins (38).  
The protein MYPT1 (myosin phosphatase target subunit 1/protein phosphatase 1 
regulatory subunit 12A), which is involved in the regulation of the interaction 
between actin and myosin, contains a PP1 interaction motif at its N-terminus that 
adheres to the consensus sequence R x x Q V/I/L K/R x Y/W, where x can be any 
residue. This motif is referred to as the myosin phosphatase N-terminal element or 
MyPhoNE lies within a five-turn α-helix, which faces hydrophobic residues in a 
shallow hydrophobic cleft on PP1 and is present in six other PP1 interacting proteins 
(39).  
A number of PP1 interacting proteins, including MYPT1 and the neurabins, which 
target PP1 to dendritic spines, are thought to possess isoform-specific docking sites 
since they interact with PP1 in an isoform-dependent manner. It is suspected that 
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these isoform-specific docking domains may be found around the N- and C-termini 
of the PP1 isoforms since they differ mainly at these termini. 
Interestingly, none of the currently described PP1 docking domains has been found 
in either isoform of human g-substrate. The section of g-substrate protein (both full 
length and short isoforms) most similar to the classical RVxF domain is a region just 
upstream of the phosphorylation motif at site 1. This section reads N- to C- terminus 
as FSEHLIKR, but when read C- to N- terminus, appears to contain a possible RVxF 
(RKILHESF) domain, although the last two residues of this possible RVxF domain 
(red) are separated by three amino acid residues (blue). 
Both variants of G-substrate possess a number of pairs of hydrophobic residues that 
could function as possible ΦΦ regions. These include the first two methionines of 
both isoforms, M1, M2. Full length g-substrate possesses two identical sequential 
hydrophobic amino acid pairs, F34, I35 and F76, I77, both of which are absent from the 
short variant because they fall in the region of full length G-substrate absent from the 
short protein. In addition to the above pairs, both full length and short G-substrate 
possess six identical hydrophobic amino acid pairs that could function as ΦΦ regions 
(Figure 1.12); Val80 Phe81, Leu85 Ile86, Met100 Ile101, Val103 Leu104, Leu133 Leu134 and 
Ile142 Val143 in the full length protein and Val29 Phe30, Leu34 Ile35, Met49 Ile50, Val52 
Leu53, Leu82 Leu83 and Ile91 Val92 in short g-substrate. 
 
 
Figure 1.12: Alignment of human G-substrate isoforms with possible ΦΦ domains highlighted. 
The phosphorylation motif is underlined, sequential hydrophobic amino acid pairs (ΦΦ) are 
highlighted, 1=full length G-substrate and 2=short G-substrate 
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1.1.5.2 Protein Phosphatase 2A 
The heterotrimeric PP2A holoenzyme results from the assembly of a common 
heterodimeric core enzyme with a regulatory subunit. The heterodimeric core 
comprises a 36 kDa catalytic subunit (subunit C) and a 65 kDa scaffolding subunit 
(subunit A, also known as PR65). This core enzyme associates with a variety of 
regulatory subunits including viral proteins, cell signalling molecules and three 
accepted families of regulatory B subunits – the B, B‟ and B‟‟ families. A fourth 
family of B subunits, the B”‟ family, which includes SG2NA, the striatins, and 
mMOB1 has been described, although controversies exist as to whether these 
subunits always associate with the core heterodimer or are only regulated by 
association with the heterodimer (40) The C subunit is encoded by two genes, 
PPP2CA and PPP2CB, which share 97 % identity and binds stably to the carboxyl-
terminal region of the A subunit. The A subunit is encoded by two genes, PPP2R1A 
and PPP2R1B, and forms a rod-shaped polypeptide consisting of 15 imperfect 
repeats. The B subunits bind to repeats 1 to 10 (the amino-terminal region) of the A 
subunit while the C subunits bind to repeats 11-15 (Figure 1.13). 
The large number of regulatory subunits PP2A associates with may provide a 
molecular basis as to how this enzyme can appropriately regulate numerous cellular 
processes, sometimes in seemingly antagonistic ways. PP2A can, for example, 
regulate the MAP kinase pathway both positively by dephosphorylating some of the 
inhibitory sites on Raf-1 and negatively by reversing some of the phosphorylation 
events downstream of Raf-1 (41). So far, PP2A has been implicated in the regulation 
of signal transduction, growth, development, metabolism, cell cycle progression and 
transformation. 
Protein phosphatase 2A has been classified as a tumour suppressor due to its role in 
the regulation of cell proliferation pathways. This is normally brought about by 
PP2A „switching off‟ signals turned on by phosphorylation. The protein Myc, for 
example, is an important regulator of cell proliferation, which is amplified in many 
human cancers and stabilised upon phosphorylation by extracellular-regulated kinase 
(ERK) (42). Upon dephosphorylation by PP2A Myc is targeted for degradation by 
polyubiquitination, reducing its abundance in the cell and affecting proliferation.  
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Figure 1.13: A model of the PP2A holoenzyme 
 
1.1.6 G-substrate Structure  
In the initial study by Aswad and Greengard (1), assessment with Sephadex G-100 
gave a Stoke‟s radius of 31Å, suggesting a molecular weight of 54KDa for the G-
substrate protein. SDS-PAGE analysis, however, indicated an apparent molecular 
weight of 23 kDa and further sedimentation coefficient analysis indicated that of G-
substrate has a molecular weight of 21.7 kDa. These results suggested that the 
protein occupied a much larger space than was expected based on its amino acid 
sequence and led to predictions that the G-substrate protein existed in an asymmetric, 
unfolded tertiary structure. A largely unfolded secondary structure is consistent with 
fact that G-substrate possesses a large number of proline residues (14 in the full 
length and 8 in the short protein) which, due to their side-chain structure destabilize 
α helix and β strand conformations. To date no solution structures exist for G-
substrate and the best model available (www.pdb.org) is a model of residues 12 to 96 
of the full length protein based on a structure that possesses only 29 % similarity to 
the section of G-substrate modeled (Figure 1.14). 
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Figure 1.14: Model of G-substrate  
Model is based on a structure of the human toll-like receptor 3 (TLR3) ectodomain (PDB accession: 
1ziwA) 
 
In this study, an attempt was made to study the structure of G-substrate using 
analytical ultracentrifugation, circular dichroism and nuclear magnetic resonance 
spectroscopy. 
 
1.1.6.1 Analytical Ultracentrifugation 
Analytical ultracentrifugation (AUC) makes it possible to monitor the sedimentation 
of macromolecules in a centrifugal field in order to characterize their hydrodynamic 
and thermodynamic properties in solution, without the need for matrices or surfaces. 
AUC is important for the study of protein interactions and protein self-association 
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and can exploit optical systems including absorbance, interference and fluorescence 
to precisely and objectively observe sedimentation in real time.  
AUC can be used to obtain two complementary views of solution behaviour. 
Sedimentation velocity (SV) provides first-principle, hydrodynamic information 
about the size and shape of molecules (43) while sedimentation equilibrium (SE) 
provides first principle, thermodynamic information about the solution molar masses, 
stoichiometries, association constants, and solution nonideality (44). Data obtained 
from AUC experiments can be analysed using a large number of data analysis 
packages available for both SV and SE (45). 
 
1.1.6.2 Circular Dichroism Spectroscopy 
Circular Dichroism (CD) is a nondestructive spectroscopic technique for the 
evaluation of protein conformation and stability under varying conditions of 
temperature and ionic strength, and in the presence of solutes or small molecules. CD 
is relatively easy to operate, requires small amount of sample and data analyses are 
fast. 
In conventional CD instruments a far-UV spectrum is collected from 180 to 250 nm, 
although further information is available in the vacuum UV region (<180 nm) which 
can be collected using synchrotron radiation CD (SRCD). A CD signal will be 
observed when a chromophore is chiral (optically active). A molecule can be 
intrinsically chiral because of its structure, for example, a C atom with 4 different 
substituents, or the disulphide bond which is chiral because of the dihedral angles of 
the C–S–S–C chain of atoms. Molecules can also be chiral when they are covalently 
linked to a chiral centre in the molecule or when placed in an asymmetric 
environment due to the 3-dimensional structure adopted by the molecule (46). 
A number of algorithms exist which use the data from far UV CD spectra to provide 
an estimation of the secondary structure composition of proteins. Most procedures 
employ basis datasets comprising the CD spectra of proteins of various fold types 
whose structures have been solved by X-ray crystallography. The different types of 
regular secondary structure found in proteins give rise to characteristic CD spectra in 
the far UV (Figure 1.15) (47). 
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Figure 1.15: Far UV CD spectra associated with various secondary structure types taken from 
Kelly et al., 2005 (46). 
Solid line, a-helix; long dashed line, anti-parallel h-sheet; dotted line, type I h-turn; cross dashed line, 
extended 31-helix or poly (Pro) II helix; short dashed line, irregular structure 
 
1.1.6.3 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance spectroscopy (NMR) exploits the magnetic properties of 
certain atoms when placed in a very strong magnetic field to determine the physical 
and chemical properties of atoms or the molecules within which the atoms exist. This 
non-destructive technique is able to provide detailed information about the structure, 
dynamics, reaction state, and chemical environment of molecules. The NMR 
phenomenon is based on the fact that nuclei of atoms have magnetic properties that 
can be utilized to yield chemical information. The main nuclei exploited in NMR are 
Structure and Regulation of G-substrate in Neurodegenerative Disease 


















present at levels below 1 % and studies involving these nuclei generally require 
isotopic enrichment by production of the molecule from media that has been 
enriched in these isotopes. NMR experiments can be 1 dimensional, involving only 
one nucleus, for example a proton (
1
H), or multi-dimensional, involving a 
combination of nuclei. Typically, a pulse of radiofrequency (RF) radiation is used to 
cause nuclei in a magnetic field to flip into the higher-energy alignment. The 
resultant RF pulse simultaneously excites nuclei in all local environments, all of 
which re-emit RF radiation at their respective resonance frequencies, creating an 
interference pattern in the resulting RF emission versus time, known as a free-
induction decay (FID). The frequencies are extracted from the FID by a Fourier 
transform of the time-based data (48). In order to compare spectra from NMR 
machines of different magnetic field strength, the frequency of resonance is plotted 
as a chemical shift, which represents the resonance frequency of a particular nucleus 
compared to that of a standard molecule scaled to the magnetic field strength of the 
NMR spectrometer and reported as parts per million, ppm because the chemical shift 
changes associated with electron density differences are about one millionth as large 
as the external magnetic field used in an NMR spectrometer. The use NMR, 
including exploitation of techniques such as the nuclear Overhauser enhancement 
(NOE) effect, which makes it possible to determine distances between atoms in 
molecules that are near each other in three-dimensional space (49) is extremely 
valuable in determining the three dimensional structure of a protein in solution. 
It is possible, using the combination of structural analysis methods described, to 
obtain valuable information on the structure of G-substrate and potentially achieve a 
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1.1.7 G-substrate in Neurodegenerative Diseases 
The occurrence of the majority of G-substrate protein in cerebellar Purkinje cells, 
which are the only output neurons of the cerebellar cortex, suggests that G-substrate 
might play a vital role in the successful execution of Purkinje cell and subsequently 
cerebellar function. Despite making up only about 10 % of total volume, the 
cerebellum has been found to contain over 50 % of the brain‟s neurons. An 
interesting analogy by Marr (50) compares the cerebellum to a language translator 
between data in the cerebrum and command sequences needed by the muscles. The 
main functions of the cerebellum include control of motor movement coordination, 
balance, equilibrium and muscle tone. G-substrate is part of the NO/cGMP/PKG 
pathway, which contributes to the process of long term depression (LTD), the 
phenomenon thought to be the cellular mechanism for cerebellar motor learning and 
it has been suggested that G-substrate is responsible for the induction of LTD in the 
cerebellum (51). Given the importance of the cerebellum and its connections to other 
parts of the brain, the involvement of cerebellar proteins in several diseases of the 
brain is not completely unexpected. 
 
1.1.7.1 Alzheimer’s Disease 
Alzheimer‟s disease (AD) is currently the most common form of progressive 
dementia known and affects several million people worldwide. This 
neurodegenerative disease, named after Alois Alzheimer, the German psychiatrist 
and neuropathologist who first described it in 1907, is characterized by the 
accumulation of β-amyloid plaques and neurofibrillary tangles in the brains of 
sufferers. The neurodegeneration associated with AD has been found to begin in the 
hippocampus, although the disease ultimately affects all parts of the brain. The exact 
pattern of neurodegeneration, however, differs from individual to individual. 
Cases of AD are mostly sporadic, although a small proportion, about 5-10 %, has 
been found to occur through autosomal-dominant inheritance. Symptoms of sporadic 
AD usually present around the age of 65, while approximately half of inherited AD 
cases are classified as „early onset‟, presenting before the age of 65 (52). 
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The current requirement for AD diagnosis in humans is the presence of 
neurofibrillary tangles in the brain. Since this can only be determined post mortem, 
prompt and definite diagnosis of the disease is rarely achieved. It has been shown 
that a large proportion of the neurofibrillary tangles found in AD brains is made up 
of hyper phosphorylated Tau protein. Under normal conditions, Tau is a neuron-
specific microtubule associated protein which is thought to be involved in the 
establishment and maintenance of neuronal polarity (53). The ability to determine 
what key events lead to tau hyper phosphorylation and its effects in vivo might make 
it possible to diagnose AD earlier and consequently reduce the impact it has on the 
lives of patients. The phosphorylation status of tau is regulated by PP2A and it has 
been shown that the PP2A holoenzyme that targets tau carries the Bβ regulatory 
subunit (41). In addition, studies of tau hyper phosphorylation induced by starvation 
in mouse brains showed that the inhibition of PP2A had a greater effect on tau hyper 
phosphorylation than the presence of some key tau kinases including cdk5 and 
TPK1/GSK3β (54). This indicates that PP2A inhibition is probably the dominant 
factor in the induction of tau hyper phosphorylation. PP2A represents a possible link 
between G-substrate and tau protein and subsequently AD. It is possible that the 
inhibitory effect of G-substrate on PP2A could contribute to the hyper 
phosphorylation of tau protein that results in the aggregation of the protein into the 
neurofibrillary tangles that are the hallmark of AD.  
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Figure 1.16: A model of the possible contribution of G-substrate to neurofibrillary tangle 
formation.  
Phosphorylated G-substrate inhibits the PP2A holoenzyme, which is consequently ineffective in the 
catalysis of tau dephosphorylation. This results in the accumulation of hyper phosphorylated tau 
protein, which facilitates aggregation and the formation of neurofibrillary tangles. 
 
1.1.7.2 Parkinson’s disease (PD) 
Parkinson‟s disease is named after the English physician James Parkinson, who in his 
1817 publication entitled „An Essay on the Shaking Palsy‟, described the disease and 
contributed to its establishment as a recognized medical condition. PD occurs when 
dopaminergic neurons in the substantia nigra are lost, decreasing dopamine levels in 
the brain. The classic disease symptoms begin to show when about 60 – 80 % of 
dopaminergic neurons are impaired or destroyed and dopamine levels decrease to 
between 20 and 50 % of normal levels. The hallmark of PD is the permanent 
degeneration of the dopaminergic neurons in the substantia nigra pars compacta 
(SNc), which leads to the characteristic movement disorders of this condition. PD 
results in the presence of intracellular inclusions, including Lewy bodies, in various 
areas of the brain, including the SNc, hypothalamus, brain stem, hippocampus and 
the cortex (55) and is defined pathologically by the presence of α-synuclein-positive 
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Lewy bodies in surviving nigral neurons combined with nigral cell loss and intact 
striatal neurons (56). Typical symptoms of PD, which are thought to occur more as a 
result of the decrease in dopamine production than the loss of neuronal cells, include 
resting tremor, muscle rigidity, bradikinesia (slowness in the execution of 
movement) and postural instability. Most PD cases are thought to be sporadic and 
present around 60 years of age. However, a small proportion of cases have currently 
been linked to mutations in a number of human genes including park1/SNCA, 
park2/parkin, park3, park4, park5/UCHL1, park6/PINK1, park7/DJ-1 and park8 (57). 
Most of these mutations results in disease onset that is earlier than in sporadic PD, 
with mutations in the E3 ubiquitin ligase, parkin resulting in disease onset as early as 
in teenage years and park7/DJ-1 mutations resulting in disease onset from 20 years of 
age. Despite the disease being known for almost 2 centuries the molecular 
mechanisms underlying PD are poorly understood and as a result there is currently 
no treatment for this devastating disease. 
Although G-substrate has not yet been determined to play a direct role in PD 
pathophysiology, research performed by Chung and coworkers (21) has suggested 
that the overexpression of G-substrate protects some dopaminergic neurons from the 
effects of PD toxins. A10 cells of the ventral tegmental area, which possess about 
three times more g-substrate than the adjacent A9 cells of the SNc, were found to be 
less susceptible to PD toxins than the A9 neurons. Observations that G-substrate 
overexpression also results in a decrease in PP2A activity raised the possibility that 
G-substrate mediates neuroprotective effects by inhibiting serine/threonine protein 
phosphatase activities. Given the adverse effects of PD on patients, further 
investigation into the mechanisms by which this differential expression of G-
substrate in adjacent neuronal cells results in differences in susceptibility to the toxic 
effects of PD might yield information to make possible the exploitation of G-
substrate overexpression in the mitigation of the effects of PD on the brain and result 
in a better prognosis and a much better quality of life for patients. 
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1.1.7.3 Spinocerebellar Ataxia type 1 (SCA1) 
Spinocerebellar ataxia (SCA) generally refers to a group of about twenty autosomal 
dominant cerebellar ataxias (ADCA). ADCAs have been classified clinically into 
three groups (58). SCA1, SCA2 and SCA3 belong to the ADCA I group and together 
with SCAs 6, 7 and 17 form part of the family of polyglutamine (polyQ) repeat 
diseases, which contains about nine known members all of which are genetically 
inherited, neurodegenerative diseases with similar pathogenesis and symptoms. 
Other members of this family include dentatorubral pallidoluysian atrophy (DRPLA) 
and Huntingtons‟s disease (HD) (59). The other SCAs have been found to arise from 
a variety of different genetic mutations. SCA1, the first spinocerebellar ataxia to be 
described, is a late onset neurodegenerative disorder, symptoms of which include 
peripheral neuropathy, oculomotor abnormalities and cognitive impairment, at 
varying degrees of severity (60). 
The protein involved in SCA1 is encoded by the ATXN1 (formerly SCA1) gene. The 
ATXN1 gene encodes a 792-830 residue protein, ataxin-1 (61), which contains the 
coding region for a polyglutamine (polyQ) tract formed by between 6 and 44 CAG 
repeats in normal alleles. Because of this variation, the product of the ATXN1 gene 
varies considerably in length depending on the length of the polyQ tract. When the 
number of repeats in non-disease proteins is greater than 20, the tract contains CAT 
(histidine) nucleotide interruptions to maintain its stability (62). In disease alleles, the 
number of repeats is between 39 and 82 and the CAT interruptions are significantly 
absent. An inverse correlation has been identified between the number of CAG 
repeats in the polyQ tract and the age of onset of the disease (63) – as the number of 
polyQ repeats increases, the age of onset of SCA1 decreases and the disease 
progresses more rapidly, resulting in a much younger age of death. Parental  
transmission has also been found to affect the length of the polyQ tract, with paternal 
transmission increasing repeat number in 63 % of cases studied, while maternal 
transmission either decreased the number of repeats or left the number unchanged in 
69 % of cases studied (62). 
Decreased expression of G-substrate mRNA was observed in the gene profiling of 
the mice with spinocerebellar ataxia type 1 (SCA1) (64). In this study, the gene 
expression pattern of the SCA1 “ataxic” transgenic mouse line (B05-ataxin-1[82Q]) 
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was compared with those of two “non-ataxic” lines (A02-ataxin-1[30Q] and K772T-
[82Q]). In addition to G-substrate, expression levels of homer homologue 3 (Homer-
3), carbonic anhydrase-like sequence, excitatory amino acid transporter 4 (EAAT4), 
inositol 1,4,5-trisphosphate receptor, type 1 (IP3R1), Purkinje cell protein 1, 
sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (SERCA3), homeotic protein 
Gtx and one expressed sequence tag (AI842002) were also significantly altered in the 
cerebellum. The observation that G-substrate expression is reduced in SCA1 presents 
the possibility that the reduction in G-substrate expression deprives the affected cells 
of the neuroprotective effects of G-substrate in a situation similar to that observed in 
the A9 dopaminergic cells in PD (21). It is also possible, however, that the 
significant decrease in G-substrate mRNA observed is merely a consequence of the 
loss of Purkinje cells, within which most of G-substrate is located, in the cerebellar 
of the ataxic mice. Further investigation into the possible role of G-substrate in 
SCA1 will provide further vital information on the details of G-substrate activity in 
the cerebellum and the possibility of exploiting G-substrate in the development of 
remedies against this debilitating disease. 
 
1.2 Aims 
In view of the neuroprotective function of G-substrate and the importance of the 
pathway within which it is found to the regulation of cellular processes in the brain, 
this study aimed to clone and express the recently described short isoform of G-
substrate and investigate whether the two isoforms of G-substrate affect PP1 and 
PP2A, the two phosphatases known to be inhibited by the full length protein, in 
similar ways and whether the two isoforms interact with the same types of rat brain 
proteins. In addition, due to the importance of protein structure to biological 
function, this study also aimed at obtaining structural information for both isoforms 
of G-substrate to shed more light on whether or not they are likely to perform the 
same functions in vivo. 
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Chapter 2: Materials and Methods 
2.1 DNA Manipulation 
2.1.1 Polymerase Chain Reaction (PCR) 
Polymerase chain reactions with pTrc plasmids carrying the Gsbs gene as template 
were performed on a PCR Sprint Thermal Cycler (Thermo Scientific) using the 
cycling conditions shown in Table 2.1. 
 
Table 2.1: PCR cycling conditions for Gsbs gene mutation 
Event Temperature Duration Number of Cycles 
Initial Denaturation 98 °C 2 min 30 sec 1 
Denaturation 98 °C 10 sec  
30 Annealing 56.4 °C 30 sec 
Extension 72 °C 2 min 30 sec 
Final Extension 72 °C 8 min 1 
 
 
Table 2.2: Components of a typical PCR  
Component  Volume (μl) Final Concentration 
sdH2O 32.5  - 
5x PCR Buffer 10.0 1 x 
dNTP Mix 4.0  200 μM of each dNTP 
Sense Primer 1.0  0.5 μM 
Antisense Primer 1.0  0.5 μM 
Template DNA 1.0  10 ng 
Phusion DNA Polymerase 0.5 1 U 
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PCR reactions were typically set up in a volume of 50µl and contained the 
components shown in Table 2.2. 
 
2.1.2 Restriction Enzyme Digestion 
DNA digestion with restriction enzymes was employed in both the preparation and 
analysis of plasmid DNA during cloning.  
 
2.1.2.1 AleI Digests 
Digestion of mutant Gsbs containing restriction sites for AleI was carried out at 37 
°C for 15 min using FastDigest
TM
 AleI (Fermentas). Reaction components for the 
digestion are shown in Table 2.3. The enzyme was inactivated after the digestion 
reaction by incubation at 65 °C. 
 
Table 2.3: Components of a typical AleI digestion reaction 
Component  Volume (μl) Final Concentration 
Nuclease-free Water  16 - 
10x FastDigestTM Buffer 3 1 x 
DNA 10  ~ 0.2 µg 
FastDigestTM AleI 1 1 FastDigestTM  Unit (FDU) 
 
 
2.1.2.2 Analytical Digests 
Plasmid digestion with EcoRI (NEB) was routinely employed to produce linearized 
plasmids for more accurate size determination using agarose gel electrophoresis. The 
reaction components of a typical analytical digest are shown in Table 2.4. 
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Table 2.4: Components of a typical EcoRI digestion reaction 
Component  Volume (μl) Final Concentration 
Nuclease-free Water  16.3 - 
10x Buffer 2.0 1 x 
Acetylated BSA 0.2 2 µg 
DNA 1.0  0.2 µg 
EcoRI 0.5 5 U 
 
 
2.1.2.3 Ligation of DNA 
Following restriction digests, ligations catalysed by T4 DNA Ligase (NEB) were 
performed. A typical 10 µl ligation reaction involved incubating the components 
shown in Table 2.5 at 16 °C overnight. 
 
Table 2.5: Components of a typical ligation reaction 
Component  Volume (μl) Final Concentration 
Nuclease-free Water  3 - 
10x Ligase Buffer 1 1 x 
DNA 5  ~ 0.1 µg 
T4 DNA Ligase 1 - 
 
 
2.1.3 Agarose Gel Electrophoresis 
Agarose gels were used at 1 % and prepared by heating 0.5 g of molecular biology 
grade agarose (Sigma) in 50 ml of Tris Acetate EDTA (TAE) buffer. After cooling 
the agarose, 5 µl of SYBR® Safe DNA stain (Life Technologies) was added and the 
gel mixture poured into a mould. The gel was submerged in TAE buffer and after 
loading DNA samples prepared with 6x loading dye (Promega), run at 200 volts for 
45.min. After adequate separation, DNA fragments were visualized using a UV 
transilluminator (UVP). 
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2.1.4 Gel Extraction of DNA 
Extraction of DNA from agarose gels was performed using either the QIAquick gel 
extraction kit (Qiagen) or the Gel Purification Kit (Promega). The procedure was, in 
each case, carried out according to the manufacturer‟s instructions. 
 
2.2 Production of Chemically Competent Escherichia 
coli 
Escherichia coli bacteria were used throughout this project. Top10 cells (Life 
Technologies) were routinely used for DNA production, while BL21 Star™ (DE3) 
pLysS (Life Technologies) and Rosetta 2 (Novagen) cells were used for protein 
production. Chemically competent cells were produced based on a modified version 
of the method developed by Hanahan (65). Between 5 and 10 ml of LB broth 
supplemented with the appropriate antibiotics was inoculated with a single colony of 
the appropriate cell line and incubated overnight at 37 °C while shaking at 220 rpm. 
This overnight culture was used to inoculate 200 ml of pre-warmed LB broth 
supplemented with the appropriate antibiotics and grown to an optical density (OD) 
at 600 nm of between 0.4 and 0.7. The total volume was then divided into 50 ml 
fractions and incubated on ice for 20 min. The fractions were then centrifuged at 
4500 g at 4 °C for 10 min. Harvested cells were resuspended in 10 ml of ice-cold 100 
mM CaCl2. The mixtures were combined and incubated on ice for 2 h. The 
competent cells were harvested by centrifuging at 4500 g at 4 °C for 10 min and 
resuspended in 2 ml of ice-cold 100 mM CaCl2 containing 20 % (v/v) glycerol. 
Aliquots of 50 µl were stored at -80 °C until required. 
 
2.3 Transformation of Escherichia coli Bacteria 
Chemically competent bacteria were transformed with plasmid vectors carrying 
genes of interest as follows: approximately 1 µg of plasmid DNA was added to 50 µl 
of chemically competent cells and the mixture incubated on ice for 30 min. The 
mixture was then incubated at 42 °C for 30 sec and returned to the ice for 2 min. 
After recovery on ice, 250 µl of SOC. medium was added to the transformed cells. 
The cells were then incubated at 37 °C, while shaking at 225 rpm for 1 h. LB agar 
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plates supplemented with the appropriate antibiotics were spread with the 
transformed cells and incubated at 37 °C overnight. Negative controls without DNA 
and positive controls with control plasmids were also set up. 
 
2.4 Small Scale ‘Mini-Preps’ of Plasmid DNA 
Ten ml of LB media supplemented with the appropriate antibiotics was inoculated 
with one bacterial colony (carrying the desired plasmid DNA) and incubated 
overnight at 37 °C while shaking at 220 rpm. The culture was subsequently 
centrifuged for 5 min at 13,000 rpm (16,060 g) in a bench top centrifuge to pellet the 
bacteria. Plasmid DNA was purified using the QIAquick mini-prep kit (Qiagen) 
according to the manufacturer‟s instructions. Purified plasmid DNA was eluted in 50 
µl of nuclease-free water and stored at -80 °C. 
 
2.5 Quantification of Plasmid DNA 
The concentration of plasmid DNA was determined using a NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific). The absorbance of 1 µl of DNA was 
measured at 260 nm using nuclease-free water as a blank and the concentration given 
in units of ng/µl. The purity of each DNA sample was given as a ratio of absorbance 
at 260 nm and 280 nm, with a ratio of ~1.8 regarded as „pure‟.  
 




G-substrate protein containing the heavier 
15
N isotope of nitrogen was expressed and 
purified for structural analysis by nuclear magnetic resonance spectroscopy (NMR). 
Uniform 
15
N isotope enrichment of the recombinant protein was achieved by 
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2.6.1 Overexpression of 15N labeled G-substrate 
Starter cultures of Rosetta 2 E. coli cells transformed with pTricHisA vectors 
carrying the gene for human G-substrate were prepared by inoculating 10 ml of LB 
containing ampicillin at 100 ng/L and chloramphenicol at 34 ng/L with a glycerol 
stock of the cells. The culture was incubated at 37 °C for 16 h while shaking at 220 
rpm.  
Five hundred ml of 5x M9 minimal growth medium (components shown in Table 
2.6) was inoculated with 4 ml of the starter culture and incubated at 37 °C with 
shaking at 220 rpm. Overexpression of the protein was induced with 1 mM of IPTG 
when the optical density (OD) at 600 nm reached 0.6. After induction, the bacterial 
culture was grown for a further 5 h after which cells were harvested by centrifuging 
at 5000 rpm (4,080 g) for 30 min in a Sorvall GS-3 rotor. 
 
2.6.2 Purification of 15N labeled G-substrate 
Harvested cells were resuspended in lysis buffer and incubated on ice for 30 min. 
Resuspended cells were then taken through five cycles in a sonic bath at 10 microns 
(15 sec on and 15 sec off) and centrifuged for 45 min at 13000 rpm (27,138 g) in a 
Sorvall SS-34 rotor.  
The supernatant from centrifugation was applied to a gravity flow column containing 
NTA agarose beads charged with nickel ions and the G-substrate protein eluted with 
increasing concentrations of imidazole. Fractions with high G-substrate 
concentration and low contamination were pooled and further purified by cation 
exchange on a column with a sulphonic acid functional group (MonoS 5/50 column) 
(Amersham Biosciences).  
Protein fractions were analyzed by SDS-PAGE and coomassie blue staining. G-
substrate protein fractions with low contamination were buffer exchanged into 20 
mM HEPES at pH 7.5 and concentrated for analysis by NMR spectroscopy. 
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Table 2.6: Composition of growth media and buffers used in the expression and purification of 
15
N G-substrate 
Preparation Components Concentration 












0.01 % (v/v) 
0.5 g/L 







Copper sulphate pentahydrate 
Sodium iodide 
Manganese sulphate pentahydrate 
Sodium molybdate dihydrate 
Boric acid 
Cobalt chloride hexahydrate 
Zinc chloride 













5x M9 Salts 
 
Sodium phosphate, dibasic 
heptahydrate 

















2.7 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis 
Proteins were routinely separated by size under denaturing conditions by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) based on the 
method of King and Laemmli (66) Polyacrylamide gels of varying concentration 
were used according to the size of protein to be analyzed. Mini-PROTEAN Tetra 
Cell apparatus (BioRad) was employed for running mini gels. Vertical slab gels were 
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produced using 5 ml of resolving gel and overlaid with 2 ml of stacking gel (Table 
2.7). Gels were fitted into the tank, which was then filled with SDS running buffer. 
Protein samples were prepared for SDS-PAGE by boiling for 5 min in Laemmli 
buffer. The protein samples were then loaded into wells created in the stacking gel 
and separated by running at 120 volts for approximately 45 min. PrecisionPlus 
Protein Markers (BioRad) were typically run alongside the protein samples to give 
an idea of protein size. Proteins were then visualized by staining with coomassie blue 
stain. 
 
Table 2.7: Buffers for SDS-PAGE 
Buffer Components Concentration 
Stacking Gel Acrylamide 
Tris-HCl, pH 6.8 
SDS 
Ammonium persulphate (APS) 
TEMED 
5 % (w/v) 
0.125 M 
0.1 % (w/v) 
0.1 % (w/v) 
0.04 % (v/v) 
Resolving Gel Acrylamide 




10-15 % (w/v) 
0.375 M 
0.1 % (w/v) 
0.1 % (w/v) 
0.1 % (w/v) 
Laemmli Buffer  
 





0.15 M  
30 % (v/v) 
6 % (w/v) 
15 % (v/v) 
0.1 % (w/v) 





0.1 % (w/v) 
Coomassie Blue Stain Acetic acid 
Methanol 
Coomassie Brilliant Blue (G250/R250) 
10 % (v/v) 
45 % (v/v) 
0.2 % (w/v) 
Destain Acetic acid 
Methanol 
10 % (v/v) 
30 % (v/v) 
 
 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 2 Materials and Methods  38 
 
2.8 Western Blotting 
Immunoblotting using antibodies specific to the proteins of interest was employed in 
the identification of recombinant proteins produced as well as proteins purified from 
tissue. Both nitrocellulose and polyvinylidene fluoride (PVDF) membranes were 
used with PVDF membranes showing better endurance for stripping and re-probing 
than nitrocellulose membranes. 
 
Table 2.8: Buffers for western blotting 
Buffer Components Concentration 





20 % (v/v) 
Ponceau S stain Ponceau S 
Trichloroacetic acid 
0.1 % (w/v) 
3 % (w/v) 





0.1 % (v/v) 
Blocking Buffer Non-fat dried milk (Marvel) 5 % (w/v) in TBS-
T 
Stripping Buffer Glycine-HCl, pH 2.0 
SDS 
0.025 M 
1 % (w/v) 
Phosphate Buffered Saline 











2.8.1 Nitrocellulose membrane 
Following separation by SDS-PAGE, the gel, membrane and blotting paper were 
immersed for 5 min in Towbin transfer buffer (Table 2.8). Proteins were transferred 
from the gel to the nitrocellulose membrane by applying a constant current of 0.2 A 
for 45 min using the Trans-blot SD semi-dry transfer apparatus (BioRad). Transfer 
efficiency was checked by staining the membrane with Ponceau S stain. After 
destaining with distilled water, the membrane was incubated for 1 h with blocking 
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buffer. The membrane was subsequently washed 3 times for 5 min each time with 
TBS-T and incubated for 1 h in primary antibody diluted to the appropriate 
concentration in blocking buffer. The membrane was washed again in TBS-T and 
incubated in the appropriate secondary antibody conjugated to horse radish 
peroxidase for 1 h at room temperature. The secondary antibody was also diluted to 
the appropriate concentration in blocking buffer. Following incubation in secondary 
antibody, the membrane was again washed in TBS-T and then incubated in the 
enhanced chemiluminescence (ECL) system (Millipore) for 5 min. Protein bands 
were visualised by exposing the membrane to autoradiographic film (Kodak) and 
developing the film using an MI-5 Automatic X-ray film Processor (Medical Index 
GmbH). 
 
2.8.2 PVDF membrane 
Due to their hydrophobicity, PVDF membranes had to be pre-wet in 100 % methanol 
prior to use. Transfer of proteins to the membrane, incubation with antibodies and 
visualization of protein bands were carried out as described in the section above 
(2.8.1) 
 
2.9 Dimerization of DJ-1 
The extent of dimerization of the DJ-1 constructs was analyzed using the 
crosslinking reagent Bis [sulfosuccinimidyl] suberate (BS
3
); 4 mM of BS
3 
was 
incubated with 10 μg of each DJ-1 construct and the reactions incubated at room 
temperature for 3 h. The samples were subsequently run on 12 % SDS-PAGE and 
analyzed with ImageJ software. To test the effect of Tanganil on dimerization of the 
DJ-1 constructs, the reaction described above was repeated for each construct with 
the addition of 5 mM of Tanganil to each reaction. 
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2.10 Purification of Protein Phosphatases from Rat 
Muscle 
The catalytic subunits of protein phosphatases 1 and 2-A were purified using an 
adaptation of the method described by Tung et al. (67) 
 
2.10.1 Preparation of Muscle Extract 
Skeletal muscle from 34 rats were homogenized in buffer A containing 1 mM PMSF, 
4 µg/ml Leupeptin and 1 mM Benzamidine and centrifuged at 5,000 rpm (4,080 g) 
for 30 min at 4 °C in a Sorvall GS-3 rotor. The pH of the lysate was adjusted to 6.1 
using acetic acid and the extract incubated at 4 °C for 15 min. The lysate was re-
centrifuged at 5,000 rpm (4,080 g) for 30 min and the pH of the supernatant adjusted 
to 7.2 with sodium hydroxide. Three hundred and fifty grams of solid ammonium 
sulphate was added for each litre of supernatant and the suspension incubated at 4 °C 
for 30 min. The suspension was then centrifuged at 5,000 rpm (4,080 g) for 40 min 
and the supernatant discarded. The precipitate was suspended in solution D. Five 
volumes of ethanol containing PMSF at 1 mM were added and the mixture 
centrifuged immediately 5,000 rpm (4,080 g) for 5 min. The supernatant was 
discarded and the precipitate extracted with solution D (without glycerol). After 
centrifuging at 13,000 rpm (27,138 g) for 15 min in a Sorvall SS-34 rotor, the 
supernatant was stored on ice and the precipitate re-extracted with solution D 
(without glycerol). The supernatants from the two extractions were combined and the 
pH adjusted to 7.2 with sodium hydroxide. Four hundred and thirty grams of solid 
ammonium sulphate was added per litre of supernatant and the suspension incubated 
for 30 min at 4 °C. The suspension was centrifuged for 40 min at 13,000 rpm (27,138 
g) and the pellet suspended in solution D. After buffer exchanging 5 times into buffer 
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Table 2.9: Buffers and Solutions used in phosphatase purification from rat muscle 
 
 
2.10.2 Affinity Purification with PolyD-Lysine Sepharose 
The resultant solution was affinity purified by batch treatment with poly D-lysine 
Sepharose and catalytic subunits of PP2-A and PP1 eluted with 250 mM and 500 
mM respectively of NaCl in solution D.  
 
2.10.2.1 Preparation of Poly D-Lysine Sepharose 
Poly D-Lysine-Sepharose was prepared using ECH Sepharose
®
4B (Pharmacia 
Biotech), Poly D-Lysine hydrobromide (Sigma-Aldrich) and 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Pierce, now Thermo 
Scientific). The pH of 5 ml of sterile water was adjusted to 5 using acetic acid. After 
dissolving 2.5 mg of poly D-lysine and 95.85 mg of EDC in the water, 2 ml of ECH 
Sepharose
®
4B gel were added to the solution and the mixture incubated at 4 °C with 
end to end rotation. After 45 min, the pH of the mixture was adjusted to 5 with dilute 
sodium hydroxide and the mixture left to rotate at 4 °C for 16 h. Following ligand 
Solution Components Concentration 
Buffer A EDTA  
EGTA, pH 7.0 
2 mM 
2 mM 





0.1 % (v/v) 





0.1 % (v/v) 





10 % (v/v) 





10 % (v/v) 





10 % (v/v) 
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coupling, the Sepharose beads were washed with 3 cycles of alternating pH 
consisting of a wash with 0.1M sodium acetate buffer at pH 4 containing 0.5 M 
sodium chloride followed by a wash with 0.1 M Tris-HCl buffer at pH 8 containing 
0.5 M sodium chloride. This was followed by a wash with distilled water to 
neutralize the pH of the beads. 
 
2.10.3 Anion-Exchange Chromatography 
Each fraction was further purified by anion exchange using a MonoQ column on an 
AKTAprime FPLC system. A gradient over 35 ml from 0 to 500 mM of sodium 
chloride in buffer E (without glycerol) was run and 500 µl fractions collected. 
 
2.11 Phosphatase Activity Assays 
The activity of tissue extracts and purified phosphatases were determined using 
either the SensoLyte pNitrophenyl Phosphatase kit from Anaspec or an adaptation of 
the method by Li et al. (68) 
 
2.11.1 SensoLyte pNitrophenyl Phosphate Phosphatase 
Assay 
Phosphatase activity was determined using the SensoLyte pNitrophenyl Phosphatase 
kit (Anaspec) according to the manufacturer‟s instructions. The presence and activity 
of a phosphatase was determined by the ability of the extract to produce p-
nitrophenol by dephosphorylating the reaction substrate, p-nitrophenyl phosphate 
(pNPP). The pNPP was provided as a solution with this kit and as a result it is not 
possible to determine what other chemicals the preparation might have contained. 
The extent of dephosphorylation was determined by measuring absorbance at 405 nm 
with a Wallac Victor
2
 plate reader (PerkinElmer). Components of the substrate 
solution used with this kit are shown in Table 2.10. 
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Table 2.10: Components of pNPP substrate solutions used with SensoLyte kit 
Component Volume in 1ml 
Assay Buffer 1 987 µl 
pNPP Stock Solution  10 µl 
DTT  3 µl 
 
 
2.11.2 Alternative pNitrophenyl Phosphate Assay 
Determination of phosphatase activity was alternatively carried out using a 
preparation of pNPP adapted from Li et al.(68). Table 2.11 shows the components of 
this pNPP substrate solution. 
 
Table 2.11: pNPP substrate solution components 
Component Concentration 
pNPP 20 mM 
MgCl2 20 mM 
Tris-HCl, pH 8.5 50 mM 




2.12 G-substrate Interacting Proteins 
G-substrate interacting proteins from rat brain were investigated by incubating G-
substrate protein bound to magnetic beads with extracts prepared from rat brain, 
separating proteins bound to G-substrate by SDS-PAGE and identifying the 
interacting proteins by MALDI-tof mass spectrometry. Controls for each 
investigation were prepared by binding bovine serum albumin (BSA) in experiments 
involving G-substrate protein or ethanolamine in experiments involving the G-
                                                 
1
 Assay buffers were prepared according to instructions contained in the kit. 
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substrate phosphopeptide, to the magnetic beads and following the same procedures 
for the G-substrate bound beads. 
 
2.12.1 Preparation of Rat Brain Extract 
Protein extracts from rat brain were prepared by homogenizing minced brains from 
male Sprague-Dawley rats in sucrose buffer (Table 2.12) containing complete 
protease inhibitor tablets (Roche). The homogenate was centrifuged for 30 min at 
50,000 rpm (109,000 g) in a TL-100 rotor (Beckman) and the supernatant filtered 
using a 0.22 µm syringe driven filter (Millipore) prior to use. 
 




 M-280 Tosylactivated magnetic beads (Invitrogen) were washed three 
times in PBS and incubated with G-substrate protein in the presence of high salt 
buffer. Coupling was achieved after rotating the mixture end to end for 16 h at 37 °C. 
The magnetic beads were subsequently incubated with blocking buffer for 1 h at 
room temperature and washed three times in PBS. 
 
2.12.3 Coupling of G-substrate phospho-peptide to 
Magnetic Beads 
Amine groups of Dynabeads® M-270 Amine magnetic beads (Invitrogen) were 
carboxymethylated by incubating the beads in 2 M iodoacetic acid in the presence of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) for 2 h at 37 
°C in the dark. The beads were then washed three times in PBS and incubated with a 
G-substrate phospho peptide of amino acid sequence CDQKKPRRKD[pT]PAL-
amide for 1 h at 37 °C. Excess iodoacetyl groups on the beads were blocked with a 
7.5 mg/ml solution of L-cysteine after which the beads were washed three times in 
PBS. 
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Table 2.12: Buffers used in the study of G-substrate interacting proteins 
Buffer Components Concentration 






Phosphate Buffered Saline 























































2.12.4 Interaction of G-substrate with Rat Brain Proteins 
Filtered rat brain extract was incubated with magnetic beads coupled to G-substrate 
protein for 16 h at 4 °C to allow interaction between the G-substrate protein and any 
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2.12.5 Analysis of Interacting Proteins 
After allowing sufficient time for interacting proteins to bind to the G-substrate 
coupled magnetic beads, the beads were washed three times in PBS and boiled for 5 
min in Laemmli buffer. After boiling, the protein sample was separated from the 
beads using a magnet and analyzed by SDS-PAGE. Proteins present were visualized 
by staining with coomassie blue stain. 
 
2.12.6 In-gel Digestion of Proteins 
Protein bands were excised from the polyacrylamide gel and incubated three times in 
wash buffer at room temperature for 30 min each time to remove SDS. The proteins 
contained in the bands were then reduced by incubating the gel bands in reducing 
solution for 1 h at room temperature. The bands were washed three times in wash 
buffer and cysteine residues in the proteins alkylated by incubating the gel bands in 
alkylating solution for 20 min at room temperature in the dark. The gel bands were 
washed three times in low wash buffer following alkylation and covered in 100 % 
acetonitrile until they turned white. The acetonitrile was then removed and the gel 
pieces allowed to dry at room temperature. The dry gel pieces were immersed in 
trypsin solution and kept at 4 °C until the gel pieces were completely swollen. 
Complete digestion of proteins was achieved after incubation at 32 °C for 16 h. 
Tryptic digests were sonicated for 10 min and zip-tipped (C18 Zip-Tip, Millipore) to 
reduce salt concentration in the samples. 
 
2.12.7 MALDI-tof Mass Spectrometry of Digested 
Proteins 
To obtain mass spectra, 1 µl of the tryptic digest was mixed with 1 µl of 10 mg/ml α-
Cyano-4-hydroxycinnamic acid (CHCA) matrix and analysed using a Voyager DE-
STR MALDI-tof mass spectrometer (Applied Biosystems). Processed spectral peaks 
were searched against non-redundant databases at the National Center for 
Biotechnology Information (NCBI) and Swissprot using Protein Prospector MSFit 
and Mascot PMF (Matrix Science) Parameters used during the database searches 
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included a maximum of 1 missed cleavage per peptide and a mass tolerance of 100 
ppm. Proteins with significant MOWSE scores (p<0.05) are reported. 
 
2.13 Circular Dichroism 
CD analysis was performed on a J-810 spectropolarimeter (JASCO) at 25 °C, using a 
0.1 cm cuvette (Starna), and with wavelengths in the far UV-range of 185–280 nm. 
Each CD spectrum represents the average of five scans (data pitch: 0.1 nm; scan 
speed: 10 nm/min; response time: 2s) and was corrected by subtraction of the 
respective spectrum obtained for its desalted buffer solution (five-scan average 
accumulation). The obtained raw spectrum signal was then converted from ellipticity 
(millidegrees) into mean residue ellipticity (degrees cm
2
 per dmol per residue), to 
allow for concentration and protein size-independent spectrum measurement for 
comparison purposes, using the Spectra Manager software. The spectra were then 
submitted to DICHROWEB (69) for deconvolution into secondary structure 
components utilizing the analysis programs CDSSTR or CONTINLL (70-72) with 
reference sets „Datasets 7‟ and SP175. 
 
2.14  Nuclear Magnetic Resonance Spectroscopy 
(NMR) 
Samples for NMR were prepared in D2O at 10 %. NMR experiments were recorded 
at 278 K on a Bruker Avance III 800 MHz spectrometer equipped with a TCI 
cryoprobe. All NMR spectra were processed with TopSpin (Bruker). Spectra were 
recorded for 1D proton, 2D nuclear overhauser effect spectroscopy (NOESY) and 2D 
total correlated spectroscopy (TOCSY) experiments. 
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Chapter 3: Expression, Purification and 
Phosphorylation of G-substrate 
3.1 Full Length G-substrate 
Full length G-substrate cDNA was obtained as an IMAGE-clone (id: BI915027) 
from the IMAGE Consortium (Genome Systems, St. Louis). The G-substrate gene 
was cloned into pTrc His A (Invitrogen) using the BamHI and XhoI sites (Figure 
3.1). DNA sequencing of the cloning product confirmed the recombinant protein was 
in frame.  
 
Figure 3.1: A Plasmid Map for Full Length G-substrate in pTrc HisA 
 
The resulting protein possessed an N-terminal 6X-Histidine tag and was 190 amino 
acids long with a molecular weight of 21,750.6 Da. 
The hexa-histidine tagged G-substrate protein was first purified by Immobilized-
Metal Affinity Chromatography (IMAC) on an NTA resin charged with nickel ions. 
Aliquots of the Ni-NTA IMAC elution fractions were analysed by SDS-PAGE and 
Coomassie staining. Fractions with high protein concentration and low 
contamination were pooled and further purified by Cation-exchange 
Chromatography on a column with a sulphonic acid functional group (MonoS) 
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(Amersham Biosciences) with a salt (NaCl) gradient of 0 M to 1 M over 25 ml of 
buffer (Figure 3.2). Peak fractions were analysed by SDS-PAGE and pooled. The 
pooled fractions were buffer exchanged into 10 mM of 2-(N-morpholino) 
ethanesulfonic acid (MES) at pH 6.0 and concentrated using a vivaspin-20 column 
(GE Healthcare).  
 
 
Figure 3.2: Chromatogram from Cation Exchange of Recombinant Full Length G-substrate 
Protein on a MonoS column.  
Green line represents salt gradient and peak represents purified full length G-substrate. 
 
G-substrate protein identity was verified by western blotting (Figure 3.3) using an 
antibody raised in sheep against the epitope QKKPRRKDTPALH, which represents 
the phosphorylation motif of G-substrate. 
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Figure 3.3: Purification of Recombinant Full Length G-substrate Protein. 
SDS-PAGE (L) and Western Blot (R) Images of Fractions from Cation Exchange of purified full 
length G-substrate. Numbers above lanes indicate fraction numbers of eluents. 
 
3.2 G-substrate ‘Variant 2’ 
Recombinant G-substrate „variant 2‟ DNA was produced by deleting the appropriate 
section from the full length G-substrate DNA as follows. 
 
3.2.1 G-substrate ‘Variant 2’ Cloning 
Four point mutations were introduced into the nucleotide sequence (Figure 3.4) of 
full length G-substrate contained in a pTrc HisA vector by polymerase chain reaction 
(PCR) using the primer sequences : 
5‟AGATCACCTAAGTGGCTGCAACGAGGGTC3‟ and 
5‟TTTCCACCCAGGTGTGTTTTCAGAACATT3‟ 
The mutations incorporated into the nucleotide sequence of full length G-substrate 
were A191G, A337C, T338A and A339C. These mutations introduced recognition 
sites for AleI to the regions flanking the portion of full length G-substrate that was 
absent in G-substrate „variant 2‟.  
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Figure 3.4: Nucleotide sequence of G-substrate. 
Portions of the full length protein absent in the short isoform are highlighted in grey, mutation sites in 
green, areas spanned by the oligonucleotide primers in pink and recognition sites for Ale1 in yellow. 
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The PCR product was cleaned up using the Wizard SV Gel and PCR clean-up system 
(Promega) and subjected to AleI digestion (see section 2.1.2) for 15 min at 37 °C. 
The enzyme was inactivated by incubating the mixture at 65 °C for 5 min and the 
digestion product cleaned up with the Wizard SV Gel and PCR clean-up system. 
After ligation with T4 DNA ligase (Promega), the mutant plasmids were transformed 
into competent Top10 cells (NEB) and grown overnight at 37°C on LB plates 
containing ampicillin at 100 ng/ml. Plasmid DNA was extracted from single colonies 
using the Qiaprep miniprep kit (Qiagen) and sequenced using the pTrc HisA vector 
primers 5‟GAGGTATATATTAATGTATCG3‟ and 
5‟GATTTAATCTGTATCAGG3‟.  
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Figure 3.5: Schematic Representation of Short G-substrate Cloning. 
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In silico translation of the DNA sequence of the mutant plasmid yielded a 144 amino 
acid protein, which represented recombinant full length G-substrate with 51 amino 
acids deleted between leucine–61 and glycine–111 (Figure 3.6), a situation identical 




Figure 3.6: Amino acid sequences of Recombinant Full Length G-substrate (F/L) and Short G-
substrate (V2) 
 
3.2.2 G-substrate ‘Variant 2’ Expression and Purification 
The pTrc HisA plasmids containing recombinant short G-substrate were transformed 
into BL21 Star™ (DE3) pLysS cells and grown on LB plates containing 
chloramphenicol at 34 ng/ml, ampicillin at 100 ng/ml and tetracycline at 12.5 ng/ml. 
A 10 ml starter culture was inoculated with a single colony from the plates and 
grown overnight at 37 °C with shaking. G-substrate „variant 2‟ protein was expressed 
in a 1 l culture of LB broth containing antibiotics as above and inoculated with the 10 
ml starter culture. Overexpression of the protein was induced with 1 mM of IPTG at 
an optical density (OD) at 600 nm of between 0.6 and 0.8. After induction, the 
bacterial cultures were grown for a further 4h after which cells were harvested by 
centrifuging at 5000 rpm (4,080 g) for 30 min in a Sorvall GS-3 rotor. 
       F/L         1 -----MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSMSTEQMQPL     45 
                          .|||||||||||||||||||||||||||||||||||||||||||| 
        V2         1 GTGKTWGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSMSTEQMQPL     50 
 
       F/L        46 EVSEDRLDKLDPRCSHLDDLSDQFIKDCDLKKKPRKGKNVQATLNVESDQ     95 
                     |||||||||||||||||                                  
        V2        51 EVSEDRLDKLDPRCSHL---------------------------------     67 
 
       F/L        96 KKPRRKDTPALHIPPFIPGVFSEHLIKRYDVQERHPKGKMIPVLHNTDLE    145 
                                       |||||||||||||||||||||||||||||||| 
        V2        68 ------------------GVFSEHLIKRYDVQERHPKGKMIPVLHNTDLE     99 
 
       F/L       146 QKKPRRKDTPALHMSPFAAGVTLLRDERPKAIVEDDEKDGDKIAI    190 
                     ||||||||||||||||||||||||||||||||||||||||||||| 
        V2       100 QKKPRRKDTPALHMSPFAAGVTLLRDERPKAIVEDDEKDGDKIAI    144 
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Harvested cells were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
10 mM Imidazole, 0.2 mg/ml Lysozyme and a complete protease inhibitor tablet 
(Roche)) and incubated on ice for 30 min. Resuspended cells were then taken 
through five cycles in a sonic bath at 10 microns (15 sec on and 15 sec off) and 
centrifuged for 45 min at 13000 rpm (27,138 g) in a Sorvall SS-34 rotor.  
The supernatant from centrifugation was applied to a gravity flow column containing 
NTA agarose beads charged with nickel ions and the G-substrate „variant 2‟ protein 
eluted with increasing concentrations of imidazole. The His-tagged G-substrate 
„variant 2‟ was further purified by anion exchange on a column with a quaternary 
ammonium functional group (MonoQ 5/50 column) (Amersham Biosciences) 
. 
 
Figure 3.7: Chromatogram from Anion Exchange of Recombinant Short G-substrate.  
Green line represents salt gradient and peak represents purified short G-substrate. 
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Fractions were analyzed by SDS-PAGE and the identity of G-substrate verified by 
immunoblotting using an antibody raised against the phosphorylation motif of G-
substrate (Figure 3.8). 
 
 
Figure 3.8: Purification of Recombinant Short G-substrate Protein. 
SDS-PAGE (L) and Western Blot (R) Images of Fractions from Anion Exchange of Recombinant 
Short G-substrate. Numbers above lanes indicate fraction numbers of eluents. 
 
 
3.3 Phosphorylation of G-substrate 
G-substrate protein was identified and named as the first endogenous substrate of 
cyclicGMP-dependent protein kinase in the brain (1). Aitken and co-workers (3) 
have shown that G-substrate is also phosphorylated by cylicAMP-dependent protein 
kinase, although less rapidly and with a preference for T119 over T68 (Figure 3.9) 
(residue numbering as for human G-substrate). Phosphorylation of both variants of 
G-substrate was catalysed by the catalytic subunit cAMP-dependent G-substrate (see 
sections 3.3.1 and 3.3.2), which was more readily available commercially than 
cGMP-dependent protein kinase. 
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Figure 3.9: Amino Acid Sequences of G-substrate Isoforms. 
Full Length (top) and Short G-substrate (bottom) showing the positions of the phosphorylation motifs 
(green) and the phosphorylateable threonines (orange). 
 
 
3.3.1 Full Length G-substrate Phosphorylation 
Phosphorylation of Full Length G-substrate was carried out in 10mM MgCl2, 50mM 
Tris-HCL, pH 7.5, 200µM ATP. About 500µg of full length G-substrate was 
incubated under the conditions above with 250units of cAMP-dependent protein 
kinase. The phosphorylation reaction was incubated at 30°C for 1 h. After 
phosphorylation, the PKA was inactivated by incubation at 65°C for 20 min and 
phosphorylation of G-substrate was confirmed by MALDI-tof mass spectroscopy. 
Phosphorylation is observed in a mass spectrum as a mass shift of 80 Daltons per 
phosphorylated amino acid. Full length G-substrate possesses two phosphorylateable 
threonines as shown in Figure 3.9 and as a result shows a mass shift of 160 Daltons 
when both phosphorylateable threonines have been phosphorylated. Figure 3.10 
shows the mass spectra of full length G-substrate before and after phosphorylation. 
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Figure 3.10: Full Length G-substrate Phosphorylation. 
Maldi-tof mass spectra of Full length G-substrate before (left) and after (right) phosphorylation 
 
3.3.2 G-substrate ‘Variant 2’ Phosphorylation 
Phosphorylation of G-substrate „Variant 2‟ was carried out in 10mM MgCl2, 50mM 
Tris-HCL, pH 7.5, 200µM ATP and 125units of cAMP-dependent protein kinase. 
The phosphorylation reaction was incubated at 30°C for 1 h, after which the PKA 
was inactivated by incubation at 65°C for 20 min and phosphorylation of G-substrate 
was confirmed by MALDI-tof mass spectroscopy. Since short G-substrate possesses 
only one phosphorylateable threonine as shown in Figure 3.9, the phosphorylated 
short protein shows a mass shift of 80 daltons when it is phosphorylated. Figure 3.11 
shows the mass spectra of short G-substrate before and after phosphorylation. 
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Figure 3.11: Short G-substrate Phosphorylation. 
Maldi-tof mass spectra of Short G-substrate before (left) and after (right) phosphorylation. 
 
 
3.3.3 Confirmation of G-substrate Phosphorylation 
To ensure that the phosphorylation observed by mass spectrometry actually occurs 
on the threonine residues within the phosphorylation motifs of both isoforms of the 
protein and not on the other serine and threonine residues present, western blot 
analysis of the phosphorylated isoforms of G-substrate was carried out using an 
antibody raised against a phosphorylated peptide with amino acid sequence identical 
to the phosphorylation motifs of the proteins. This phospho G-substrate antibody was 
a kind gift from Professors Paul Greengard and Angus Nairn (Rockefeller 
University). Results from western blotting (Figure 3.12) confirmed that 
phosphorylation had occurred on the correct residues. 
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G-substrate protein was successfully expressed and purified. Protein yield was 
enhanced by the use of Rosetta2 E. coli cells, which made those human codons 
usually rare in E. coli bacteria available during translation. In the production of the 
short G-substrate protein, BL21 Star™ (DE3) pLysS cells, which served the same 
purpose, were used.  
Both isoforms of G-substrate were found to run at molecular weights different from 
their predicted weights on SDS-PAGE. Analysis by MALDI-tof mass spectrometry, 
however, showed the proteins had the correct molecular weight. 
Western blot analysis of „variant 2‟ G-substrate showed bands that were less intense 
than those obtained for full length G-substrate even when comparable amounts of the 
proteins were used. This is most likely due to the possession by short G-substrate of 
one phosphorylation motif while full length G-substrate possesses two. It is possible 
that since the antibody used in the western blot analysis was raised against the 
phosphorylation motif, the full length protein, which potentially binds two 
molecules, will give a stronger signal than the short protein, which potentially binds 
only one antibody molecule. 
Both isoforms of G-substrate were successfully phosphorylated with the catalytic 
subunit of cAMP-dependent protein kinase. The fact that the full length protein 
possessed twice as many phosphorylation sites as the short isoform was evidenced by 
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the requirement of approximately double the enzyme concentration to effect 
complete phosphorylation within the times observed for the short isoform. 
Phosphorylation was detected by MALD-tof mass spectrometry as an 80 kDa shift in 
mass for every phosphate group added to the isoforms, resulting in a shift of 80 kDa 
for the short protein and 160 kDa for the full length protein. 
Western blot analysis using an antibody raised against the phosphorylation motif of 
G-substrate, which is identical in both variants confirmed that phosphorylation had 
occurred on the correct threonine residues. 
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Chapter 4: Phosphatase Inhibition by 
Phosphorylated G-substrate  
Inhibition of protein phosphatase activity by G-substrate protein has been studied 
extensively. Opinions differ, however, regarding which protein phosphatase, PP1 or 
PP2A is inhibited by G-substrate most effectively. Although it has been established 
that phosphorylated full length G-substrate does inhibit PP1 and PP2A, the role of 
the short G-substrate isoform as a phosphatase inhibitor has yet to be established. 
The experiments in this section are described in section 2.11 and were designed to 
investigate the effects of both phosphorylated and unphosphorylated short G-
substrate on protein phosphatase activity and to compare the phosphatase inhibitory 
effect of this form of G-substrate to that of full length G-substrate. 
 In order to eliminate the effect of any p-nitrophenol present at the start of the 
reactions and ensure that all p-nitrophenol measured is due to the dephosphorylation 
of pNPP, the absorbance values at time zero for each reaction were subtracted from 
the absorbance values obtained for subsequent time points. As a result, curves 
showing the effects of the different forms of G-substrate on the activities of the 
phosphatases investigated show activity values starting at t = 2.5 min for assays 
investigating PP1 gamma and PP5 activities and at t = 5 min for all other assays. In 
these curves, relative activity values below the control indicate and inhibition of 
phosphatase activity while relative activity above the control suggests and 
enhancement of phosphatase activity. 
Where the effects of different concentrations of the G-substrate variants on 
phosphatase activity are presented as histograms, the values plotted are taken at t = 
25 mins for all the experiments conducted because at this point, the phosphatase 
activities of the different phosphatases were found to be optimum under all the 
conditions used.  
In all the curves shown in this section, each point represents the mean of two values 
taken from two identical reactions under the same conditions.  Experiments for all 
the results shown in this chapter were repeated on at least two different occasions 
with consistent results for every occasion. 
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4.1 Inhibition of Total Phosphatase Activity of Rat 
Brain Extract 
Protein extracts were prepared from the brains of male Sprague Dawley rats 
according to the protocol described in „Materials and Methods‟ in a buffer containing 
Triton X-100 and protease inhibitors. Protein phosphatase assays were performed 
using the SensoLyte pNPP Protein Phosphatase Assay Kit (Colorimetric) from 
Anaspec. Experiments were set up to select the activity of either protein phosphatase 
1 or protein phosphatase 2A in the rat brain extract. Phosphatase activity was 
determined by monitoring the release of p-nitrophenol at 405nm using a Wallac 1420 
VICTOR
2
 plate reader from Perkin Elmer. 
 
4.1.1 Inhibition of Rat Brain PP1 Activity 
Assays of rat brain PP1 confirmed the fact that phosphorylated full length (F/L) G-
substrate reduces the activity of PP1 in the brain. Dephosphorylation assays (Figure 
4.1) performed in the presence of the phosphorylated full length protein showed 
phosphatase activity below that of the uninhibited control within 25 min of 
commencing the reaction, with phosphatase activity dipping to less than 30 % within 
1 hr. The unphosphorylated full length protein, however, did not reduce phosphatase 
activity and instead seemed to enhance PP1 activity with activity of the reaction 
remaining above 100 % for the duration of the observations. Both phosphorylated 
and unphosphorylated short G-substrate however showed higher phosphatase activity 
than the uninhibited reaction for the first 45 min after which PP1 activity in the 
presence of the unphosphorylated short protein dipped to below 30 % within 10 min 
and remained at approximately that level for the duration of the observation. These 
observations indicate that although phosphorylated G-substrate effectively inhibits 
total brain PP1 activity, the unphosphorylated full length protein and both 
phosphorylated and unphosphorylated short G-substrate either have no effect on or 
enhance total activity of PP1 in the brain.  
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Figure 4.1: Dephosphorylation of pNPP by Rat Brain PP1 in the presence of G-substrate 
Variants. 
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
 
 
4.1.2 Inhibition of Rat Brain PP2A Activity 
Both short and full length G-substrate, when unphosphorylated, did not seem to 
adversely affect the activity of total brain PP2A (Figure 4.2), with activity in the 
presence of both variants remaining above the level of the uninhibited reaction for 
the duration of the observation. When phosphorylated, however, both variants of G-
substrate markedly reduced the activity of the brain PP2A, with the phosphorylated 
short protein reducing activity further (below 60 %) than the phosphorylated full 
length protein, which reduced total brain PP2A activity to about 90 % of the 
uninhibited reaction. 
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Figure 4.2: Dephosphorylation of pNPP by Rat Brain PP2A in the presence of G-substrate 
Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 





4.2 Inhibition of Phosphatase Activity of Rat 
Cerebellar and Cerebral Extracts 
Since both the PP1 and PP2A holoenzymes consist of several subunits which have 
been determined to vary appreciably between the different tissue types, separate 
extracts of PP1 and PP2A were prepared from the cerebella and cerebra of adult rats 
and assayed for phosphatase activity in the presence of G-substrate variants. 
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4.2.1 Inhibition of Cerebellar PP1 Activity 
In cerebellar extracts, the presence of all the G-substrate forms resulted in PP1 
activity levels (Figure 4.3) falling below 100% for the duration of the observations.  
PP1 activity in the presence of the unphosphorylated isoforms seemed to recover 
more rapidly after approximately 40 mins compared with activity in the presence of 
the phosphorylated proteins. This recovery suggests that the phosphorylated G-
substrate variants are more resistant to factors present in the cerebellar extract that 
might affect interaction with PP1. Such factors might include proteases, which 
degrade the proteins and subsequently abolish their effects on PP1 or other regulators 
of PP1 that might abolish interaction of G-substrate variants with the PP1 
holoenzyme. It is also possible that the ability of phosphorylated full length G-
substrate to inhibit cerebellar PP1 for a longer period than the phosphorylated short 
protein is due to differences in their resistance to dephosphorylation by the 
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Figure 4.3: Dephosphorylation of pNPP by Cerebellar PP1 in the presence of G-substrate 
Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
 
 
In the presence of varying concentrations of the G-substrate isoforms (Figure 4.4), 
phosphorylated short G-substrate consistently results in lower PP1 activity than the 
unphosphorylated short protein. Total cerebellar PP1 activity below that observed in 
uninhibited reactions (representing PP1 inhibition), however, is observed only after 
the phosphorylated short protein reaches a concentration of 2 µM. PP1 activity 
remained at 90 % when the phosphorylated short G-substrate concentration was 
increased to 5 µM, while activity in the presence of unphosphorylated short G-
substrate remains consistently above 100 %.  
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In contrast, the presence of phosphorylated full length G-substrate results in activity 
levels lower than 100 % for all the concentrations studied, with the greatest 
inhibition in the presence of 5 µM phosphorylated full length G-substrate. 
 
Figure 4.4: Activity of Cerebellar PP1 in the presence of Different G-substrate Concentrations.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control).  
 
 
4.2.2 Inhibition of Cerebellar PP2A Activity 
In the cerebellar extracts, PP2A activity was least affected by unphosphorylated short 
G-substrate, which reduced phosphatase activity to about 90 % in approximately 15 
min (Figure 4.5) The unphosphorylated full length protein and the phosphorylated 
forms of both variants all reduced PP2A activity to between 60 % and 75 % of the 
uninhibited reaction from the start of the experiment and reduced PP2A activity was 
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maintained throughout the observation. Unlike PP1, cerebellar PP2A activity was 
most affected by phosphorylated short G-substrate, which resulted in an 
approximately 30 % reduction in phosphatase activity throughout the observation. 
Both phosphorylated and unphosphorylated full length G-substrate reduced 
cerebellar PP2A activity to similar levels, with the phosphorylated form maintaining 
a slightly higher level of phosphatase inhibition than the unphosphorylated form. 
 
 
Figure 4.5: Dephosphorylation of pNPP by Cerebellar PP2A in the presence of G-substrate 
Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
 
 
The presence of both phosphorylated and unphosphorylated forms of the two G-
substrate isoforms resulted in reduced cerebellar PP2A activity across all the protein 
concentrations studied (Figure 4.6). The greatest inhibition was observed for 
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phosphorylated short G-substrate, which reduced PP2A activity by approximately 
55% at a concentration of 0.5 µM. PP2A activity levels remained largely stable in 
higher concentrations of G-substrate protein, with both the phosphorylated and 




Figure 4.6: Activity of Cerebellar PP2A in the presence of Increasing Concentrations of 
Unphospho- and Phospho-Short G-substrate.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
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4.2.3 Inhibition of Cerebral PP1 Activity 
In cerebellar preparations, the greatest inhibition of PP1 activity occurred in the 
presence of the phosphorylated forms of both isoforms (Figure 4.7), with activity in 
the presence of both unphosphorylated forms remaining identical throughout the 
duration of the reaction. For the first 40 mins of the reaction, the presence of the 
phosphorylated full length protein resulted in slightly more inhibition of cerebellar 
PP1 activity than was observed for the phosphorylated short protein. After 40 mins, 
however, both phospho-forms inhibited the phosphatase activity of the cerebellar 
extract to the same extent. 
 
 
Figure 4.7: Dephosphorylation of pNPP by Cerebral PP1 in the presence of G-substrate 
Variants. 
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 4 Phosphatase Inhibition by Phosphorylated G-substrate  72 
 
In cerebral preparations, although both forms reduced PP1 activity, the extent of 
inhibition in the presence of the unphosphorylated short protein remained constant 
across all the concentrations tested (Figure 4.8). The phosphorylated short protein 
only showed a slight increase in inhibition with increasing concentration. The 
presence of the unphosphorylated full length protein reduced PP1 activity to a greater 
extent than the phosphorylated protein at concentrations less than 5 µM. Above this, 




Figure 4.8: Activity of Cerebral PP1 in the presence of Increasing Concentrations of 
Unphospho- and Phospho- G-substrate.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). 
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4.2.4 Inhibition of Cerebral PP2A Activity 
The effect of the G-substrate isoforms on cerebral PP2A was very similar to that 
observed in the cerebellar preparations, with both phosphorylated forms reducing 
PP2A activity to a greater extent than the unphosphorylated forms. Unlike the 
cerebellar PP2A where all the isoforms reduced phosphatase activity, the presence of 
one form of G-substrate, the unphosphorylated short isoform, resulted in cerebral 
PP2A activity that was essentially enhanced for the duration of the reaction (Figure 
4.9).  This variation in the effect of unphosphorylated short G-substrate on PP2A 
activity in the different areas of the brain might be a hint at the existence of subtle 
differences in the roles of the various isoforms of G-substrate in different areas of the 
brain and the possibility that since different PP2A holoenzymes are targeted to 
different areas by their B-subunits (73), the different G-substrate forms might 
interact preferentially with different holoenzymes of PP2A in the different areas of 
the brain.  
 
Figure 4.9: Dephosphorylation of pNPP by Cerebral PP2A in the presence of G-substrate 
Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
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When varying concentrations of the G-substrate isoforms were studied (Figure 4.10), 
all forms except the phosphorylated short protein reduced PP2A activity of the 
cerebral extract to approximately constant levels up to 2 µM after which the 
phosphorylated short protein produced the most inhibition with the effects of the 
other forms remaining largely unaltered. 
 
 
Figure 4.10: Activity of Cerebral PP2A in the presence of Increasing Concentrations of G-
substrate.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
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The activities of PP1 gamma and PP5, kindly provided by Professor Patricia Cohen 
of the University of Dundee were investigated in the presence of G-substrate. 
Although G-substrate has been shown to inhibit PP1 purified from mammalian brain, 
no information on its effect on specific PP1 isoforms is currently available. 
 
4.2.5 Inhibition of PP1 Gamma Activity 
The gamma isoform of PP1 is important for cell cycle regulation with experiments 
showing the selective loading of a pool of PP1γ onto chromatin at anaphase (74). 
Both phosphorylated and unphosphorylated forms of short G-substrate reduced the 
activity of PP1γ as can be seen in Figure 4.11. The unphosphorylated short form was, 
however, the most potent inhibitor of PP1γ activity. The unphosphorylated forms of 
both G-substrate isoforms reduced PP1γ activity to approximately the same extents, 
while the presence of the phosphorylated full length protein enhanced PP1γ activity, 
resulting in phosphatase activity that remained consistently higher than the 
uninhibited control reaction.  
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Figure 4.11: Dephosphorylation of pNPP by PP1 Gamma in the presence of G-substrate 
Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
 
4.2.6 Inhibition of Protein Phosphatase 5 Activity 
Protein phosphatase 5 (PP5) is a serine threonine phosphatase, which has been 
implicated in a wide range of cellular processes including cell cycle arrest, the 
cellular heat shock response and DNA damage repair via the p53 and ATM/ATR 
pathways (75). 
The small pool of PP5 associated with microtubules has been shown to 
dephosphorylate abnormally phosphorylated tau protein in the presence of 
arachidonic acid in vitro (76). This observation suggests an important role for PP5 in 
conditions such as Alzheimer‟s disease, where it could potentially undo the abnormal 
tau protein phosphorylation that results in the formation of neurofibrillary tangles. 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 4 Phosphatase Inhibition by Phosphorylated G-substrate  77 
 
To explore the possibility that G-substrate affects the activity of other 
serine/threonine phosphatases, the effect of phosphorylated and unphosphorylated 
forms of both G-substrate isoforms on PP5 dephosphorylation of pNPP was 
investigated. 
Unphosphorylated forms of both G-substrate isoforms reduced PP5 activity after 
about 5 mins, while the phosphorylated full length isoform of G-substrate inhibited 
PP5 activity after 15 mins (Figure 4.12). The phosphorylated short isoform, however, 
resulted in phosphatase activity that remained very close to the uninhibited control 
reaction after the first 15 mins, suggesting that phosphorylated short G-substrate has 
little or no effect on PP5 activity. The unphosphorylated full length protein was 
found to be the most inhibitory, reducing PP5 activity to less than 70 % after 5 min 
and maintaining the lowest PP5 activity for the duration of the experiment.  
 
 
Figure 4.12: Dephosphorylation of pNPP by PP5 in the presence of G-substrate Variants.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a 
percentage of activity in the uninhibited reaction (control). In each reaction, 10 µM of the appropriate 
G-substrate form was used. 
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4.3 Purification of Protein Phosphatases 1 and 2-A 
from Rat Muscle 
In order to investigate the effect of the G-substrate isoforms on PP1 and PP2A 
catalytic subunits (PP1c and PP2Ac), these were purified from rat skeletal tissue as 
described in section 2.10 and their activities assayed in the presence of 
phosphorylated and unphosphorylated forms of both G-substrate isoforms. 
Fractions obtained from ion exchange purification, detailed in section 2.10.3 of the 
„Materials and Methods‟ chapter were tested for phosphatase activity. Fractions with 
the highest activity were pooled and the effects of phosphorylated and 
unphosphorylated forms of both G-substrate isoforms on the pooled fractions tested 
using pNPP as a substrate. 
.
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4.3.1.1 Activity of Purified PP1  
 
Figure 4.13: Overlay of UV absorbance and enzyme activity traces of PP1c fractions purified from rat skeletal muscle.   
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Figure 4.14: Activity of PP1c from Rat Skeletal Muscle on Different Concentrations of G-substrate.  
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a percentage of activity in the uninhibited reaction (control).  
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Phosphatase assay of the catalytic subunit of PP1 (Figure 4.14) showed lower 
activity in the presence of unphosphorylated short G-substrate than the 
phosphorylated short isoform, indicating that the unphosphorylated short protein is a 
better inhibitor of  PP1c than the phospho-form of the same isoform. This pattern of 
PP1c inhibition by short G-substrate remained the same for virtually all the 
concentrations investigated. 
At concentrations lower than 1.2 µM for unphosphorylated full length G-substrate 
lower PP1c activity was observed than with its phosphorylated form. At 
concentrations of 1.2 µM and higher, however, as expected, the phosphorylated full 
length protein shows a greater inhibition of PP1c than the unphosphorylated form 
suggesting the existence of an apparent threshold of phosphorylated G-substrate 
concentration required for PP1c inhibition. Both forms of short G-substrate resulted 
in PP1c activity higher than or about the same as for full length G-substrate at the 
same concentration. While at concentrations lower than this apparent threshold, both 
forms of short G-substrate resulted in greater inhibition of PP1c activity than 
observed for both forms of the full length protein. 
These observations suggest the possibility of a concentration dependent activation of 
G-substrate inhibition of the PP1 catalytic subunit with aberrant effects observed for 
the phosphorylated and unphosphorylated forms of the two isoforms dependent on 
whether or not their concentrations exceed the threshold. 
Phosphorylated and unphosphorylated forms of both short and full length G-substrate 
affected the catalytic subunit of PP2A to approximately the same extent across the 
protein concentrations studied (Figure 4.16: Activity of PP2Ac in the presence of 
Different Concentrations of G-substrate.). This suggests that, as observed in extracts 
of whole brain, cerebra and cerebella, all forms of G-substrate protein are able to 
inhibit this PP2A. 
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4.3.1.2 Activity of Purified PP2A
 
Figure 4.15: Overlay of UV absorbance and enzyme activity traces of PP2Ac fractions purified from rat skeletal muscle
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Figure 4.16: Activity of PP2Ac in the presence of Different Concentrations of G-substrate. 
Relative activity was determined by expressing enzyme activity in the inhibited reaction as a percentage of activity in the uninhibited reaction (control) 
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.Table 4.1: Summary of Effects of G-substrate variants on the Activities of different forms of 
PP1 and PP2A.  
The effect of the G-substrate variants on activities of the phosphatases have been represented with 
stars (*), with **** indicating the greatest inhibition of phosphatase activity and * indicating the 




















** * * * ** * **** *** 
PHOSPHO – 
SHORT 
* **** **** **** *** *** *** * 
UNPHOSPHO- 
FULL LENGTH 
*** ** *** ** ** ** *** **** 
PHOSPHO – 
FULL LENGTH 




Table 4.1 summarizes the effects of the different variants of G-substrate on the 
different phosphatases studied. The two variants of human G-substrate affected PP1 
and PP2A in brain extracts to different extents. The phosphorylated short G-substrate 
isoform was the most effective at inhibiting both PP1 and PP2A from rat cerebella, 
while the phosphorylated full length protein inhibited both PP1 and PP2A from rat 
cerebra most effectively. 
Where the activities of these phosphatases in whole brain extracts were studied, the 
phosphorylated full length G-substrate protein was most effective at inhibiting PP1, 
while the presence of the phosphorylated short G-substrate isoform produced the 
greatest reduction in activity of whole brain PP2A. 
The phosphorylated forms of both isoforms of G-substrate protein affected the 
activities of PP1 and PP2A in the different brain regions to greater extents than their 
unphosphorylated forms, confirming observations by other researchers that G-
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substrate becomes a potent inhibitor of protein phosphatases when phosphorylated 
(8,9). It is possible, however, that the phosphorylation of G-substrate is not necessary 
for the regulation of other phosphatases since experiments with PP5 showed the 
unphosphorylated full length G-substrate protein showing the greatest inhibition, 
followed by the unphosphorylated short isoform, with the phosphorylated short 
isoform especially showing very little effect on PP5 activity. 
The observation that the different isoforms of G-substrate affect the activities of PP1 
and PP2A in different areas of the brain to different extents suggests a specialization 
of the G-substrate variants for the regulation of PP1 and PP2A activities in different 
brain areas, with the phosphorylated full length protein regulating PP1 and PP2A 
more effectively in the cerebrum and the phosphorylated short G-substrate isoform 
regulating the same phosphatases more effective in the cerebellum.  
It must be noted, however, that in assaying brain PP1 and PP2A, no discrimination is 
made between the different holoenzymes of PP1 and PP2A, which localize to 
different brain areas (see sections 1.1.5.1 and 1.1.5.2) and as a result, the observed 
effects of the G-substrate isoforms on the phosphatase activities of these preparations 
may be a combination of the effects of the G-substrate isoforms on the different PP1 
and PP2A holoenzymes present in the brain. 
Observations that both phosphorylated and unphosphorylated forms of the two G-
substrate isoforms reduce cerebellar PP2A activity even at low concentrations 
suggest that PP2A regulation is an important function of G-substrate in the 
cerebellum, where it is most abundant. Such regulation of cerebellar PP2A, which is 
an important phospho-tau phosphatase, provides a possible link between G-substrate 
activity and Alzheimer‟s disease via tau protein hyperphosphorylation. 
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Chapter 5: G-substrate Structure 
Obtaining structural information is vital to the study of any protein as structure and 
function are inextricably linked such that the loss of structure often results in a loss 
of protein function, ultimately leading to the destruction of the protein by dedicated 
cellular processes. Structural information is also essential in drug design and might 
also assist in the development of inhibitors to protect against a proteins less desirable 
effects. 
G-substrate has been linked to the protection of A9 dopaminergic neurons from 
Parkinson‟s disease toxins and information on its structure will assist in the 
identification of any other proteins it might interact with in performing this function, 
leading to a better understanding of the process and a possible remedy for the 
devastation of dopaminergic cells caused by Parkinson‟s disease. 
Previous attempts by other members of the Aitken research group to solve the crystal 
structure of G-substrate were unsuccessful as extensive crystal screens set up did not 
yield any crystals from which the structure of the protein could be elucidated. The 
inability to obtain crystals of G-substrate led to the decision in this project to study 
G-substrate structure in solution. 
 
5.1 Analytical Ultracentrifugation of G-substrate 
To determine the conformation of G-substrate in solution, analytical 
ultracentrifugation was performed in conjunction with Dr Olwyn Byron of Glasgow 
University. Sedimentation velocity (SV) and sedimentation equilibrium (SE) 
experiments were employed to determine the size distribution and self-association 
characteristics of full length G-substrate protein. Results obtained indicate that the 
native state of G-substrate is a monomer (Figure 5.1). Since short G-substrate only 
differs from the full length protein by the loss of a 51 amino acid section, it can be 
inferred that short G-substrate also exists as a monomer. 
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Figure 5.1: Sedimentation velocity analysis of G-substrate. 




5.2 In-silico Structure Prediction 
 
5.2.1 Secondary structure 
Online structural prediction software (www.predictprotein.org) was used to 
investigate the most likely structures of the G-substrate variants from their amino 
acid sequences. Results obtained indicate that both variants of G-substrate exist as 
largely unstructured proteins. A summary of the proportion of each secondary 
structure type possessed by each G-substrate variant is presented in Table 5.1 below. 
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Short G-substrate was predicted to be slightly more structured than the full length 
protein, possessing about 10 % less loop structure. For both variants, however, 
predictions for the recombinant protein suggested a structure less compact than that 
predicted for the native proteins. Figure5.2 shows a representation of the predicted 
secondary structures for the two variants and Figure 5.3 and Figure 5.4 present the 
predicted structures for the native and recombinant proteins for each variant side by 
side for comparison. 
 
Table 5.1: Percent of secondary structure types present in G-substrate variants as predicted by 
online software at predictprotein.org 
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Figure5.2: Secondary Structure Prediction for G-substrate variants from the PSIPRED Protein Structure Prediction Server (http://bioinf.cs.ucl.ac.uk/psipred) 
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Figure 5.3: Secondary Structure Prediction for native and recombinant short G-substrate variants from the PSIPRED Protein Structure Prediction Server 
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Figure 5.4: Secondary Structure Prediction for native and recombinant full length G-substrate from the PSIPRED Protein Structure Prediction Server 
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5.2.2 Non-Regular Secondary Structure 
NOn-Regular Secondary Structure predictor (NORSp) software available at 
www.predictprotein.org was used to investigate the presence of disordered regions in 
the G-substrate protein variants. The software predicted vast regions lacking regular 
secondary structure for the recombinant forms of both full length and short G-
substrate. The prediction also showed the native full length protein to be entirely 
disorded from residue 33 to 155 but interestingly, despite possessing 104 amino acids 
completely identical to the full length protein, short G-substrate was predicted to 
possess no disordered regions at all by the NORS software. Another protein, 
DARPP-32, which also potently inhibits protein phosphatase 1 when phosphorylated 
on a threonine residue, was predicted to be entirely disordered by the same software. 
This large extent of disorder in the protein structure might explain our lack of 
success in obtaining crystals for G-substrate. 
 
5.3 Circular Dichroism 
Two dimensional structures of the G-substrate variants were further investigated by 
Circular Dichroism (CD) spectroscopy. Using the CDSSTR and CONTIN analysis 
methods full length G-substrate was found to exist in solution as 9.9 % helix, 16.6 % 
strand, 14.5 % turns and 59.0 % unordered structure (Figure 5.6), while short G-
substrate was found to exist as 8.6 % helix, 17.3 % strand, 14.4 % turns and 59.6 % 
unordered structure(Figure 5.5). Phosphorylation was shown to significantly alter the 
structures of both isoforms of G-substrate. As shown in Figure 5.7, the phospho-
forms of the proteins possessed considerably reduced levels of ellipticity, implying 
that upon phosphorylation, both G-substrate variants lose a substantial degree of 
secondary structure, becoming less compactly folded and more disordered. 
Full length G-substrate is known to tolerate temperatures up to 90 °C and the extent 
to investigate whether short G-substrate is also able to withstand high temperatures 
cd spectra were acquired for both variants at 85°C followed by acquisition at 25°C. 
In both cases, the significant loss of secondary structure observed at 85°C was almost 
entirely recovered upon cooling to 25°C, indicating that short G-substrate is equally 
tolerant of high temperatures. 
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Figure 5.5: Representative Deconvolution for Short G-substrate 
Structure and Regulation of G-substrate in Neurodegenerative Disease 





Figure 5.6: Representative Deconvolution for Full Length G-substrate 
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Figure 5.7: Overlays of CD spectra showing differences in ellipticity between unphosphorylated and phosphorylated G-substrate variants 
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Figure 5.8: Overlays of CD spectra showing differences in ellipticity between G-substrate protein samples at different temperatures
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5.4 Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance (NMR) spectroscopy was employed to further investigate the 
structure of the G-substrate variants and possibly obtain a solution to their three dimensional 
structures. One dimensional proton spectra obtained for both variants were very similar 
(Figure 5.9), indicating that in solution, their structures were very much alike. As very little 
structural information can be obtained from 1D data due to its complexity, NOESY spectra, 
which map the correlations between protons in a molecule providing more useful structural 
information, were acquired to further investigate structure. 
Data obtained from NOESY experiments showed the presence of very few cross peaks, 
representing protons which are very close together in the amino acid sequence and those 
brought close as a result of interactions due to tertiary structure. This suggests that in general, 
both variants of G-substrate possess very little structure. At the same intensity, full length G-
substrate showed slightly more cross peaks than short G-substrate (Figure 5.10), suggesting 
that the structure of full length G-substrate in solution is slightly more compact than that of 
short G-substrate. 
Comparison of NOESY spectra obtained from phosphorylated forms of the G-substrate 
variants with spectra from unphosphorylated samples (Figure 5.11) showed a difference in the 
population of cross peaks which indicated that upon phosphorylation, fewer interactions 
occurred between the nuclei, corresponding to a reduction in compact structure of the proteins 
upon phosphorylation. 
Batches of the G-substrate variants labelled with the heavier Nitrogen-15 isotope were 
produced to make possible the assignment of specific amino acids to the peaks obtained from 
the NMR experiments. This assignment, which would ultimately lead to a solution structure 
for G-substrate, could not be pursued further due to unforeseen logistical issues.
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Figure 5.9: Overlay of 1D NMR spectra for full length (red) and short (blue) G-substrate 
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Figure 5.10: Overlay of NOESY contour plots for full length (blue) and short (red) G-substrate 
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Figure 5.11: Overlays of NOESY contour plots for unphosphorylated (blue) and phosphorylated (red) samples of short (A) and full length (B) G-substrate
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5.5 Discussion 
Data obtained from CD and NMR agreed to a large extent with predictions (1) that both 
variants of G-substrate are largely unstructured, indicating that the prediction that short G-
substrate possessed no non regular structure at all was erroneous, possibly brought about by 
the inability of the software to adequately predict interactions between the amino acids in 
solution, which may not be entirely obvious from the amino acid sequence alone. The portion 
of full length G-substrate missing from the short variant is proline rich, with 6 residues in a 51 
amino acid section. This presented the possibility that the short G-substrate isoform would be 
more compactly folded than the full length protein due to the fact that the presence of proline 
disrupts secondary structure including α helixes and β sheets, leading mainly to the formation 
of loops and turns. Results however revealed that the full length protein was slightly more 
compact in structure than the short variant. 
G-substrate is not dissimilar to other phosphatase inhibitors in terms of its existence as a 
predominantly disordered protein. Inhibitor 1 and DARPP-32 are both potent inhibitors of 
protein phosphatase 1 that, like G-substrate, require phosphorylation on a threonine residue 
for activation of their phosphatase inhibitory activities, and are both predominantly 
unstructured (77). The existence of some structural similarity among these proteins is 
highlighted in Figure 5.12, which shows an alignment of the amino acid residues surrounding 
the threonine residues important for phosphatase inhibitory activation in G-substrate, 
Inhibitor-1 and DARPP-32. The alignment also reveals that for all three proteins the 
phosphorylateable threonines are mainly surrounded by basic and small, hydrophobic amino 
acids. 
The nuclear inhibitor of protein phosphatase 1, NIPP1, has also been shown to possess an 
intrinsically disordered PP1-binding domain (37). This evidence suggests that structural 
disorder may be vital to their function as protein phosphatase 1 inhibitors. The observation 
that G-substrate becomes even more disordered upon phosphorylation, a requirement for its 
phosphatase inhibition activity, is interesting and suggests an important role for structural 
disorder in the mechanism of protein phosphatase 1 inhibition.  
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Figure 5.12: Alignment of partial amino acid sequences for DARPP-32, G-substrate and Inhibitor-1 (I-1). 
The amino acid sequences surrounding the two phosphorylation sites in full length G-substrate are denoted F/L 
Gsub1 and F/L Gsub1. Threonine residues phosphorylated to activate PP1 inhibitory activity are coloured blue. 
Basic amino acids are magenta and small, hydrophobic amino acids in red. 
 
The proteins discussed above and other inhibitors of PP1, although largely unstructured, have 
been found to fold upon binding to PP1. It would be interesting, therefore, to determine what 
conformation G-substrate assumes upon interaction with PP1 and PP2A. It would also be 
interesting to determine whether G-substrate gains any structure during the brief interaction 
with cGK that results in its phosphorylation in vivo. Since our results have shown that G-
substrate becomes even more unstructured after phosphorylation, this would provide 
interesting insight into the extent of structural flexibility G-substrate possesses. 
 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 6 G-substrate Interacting Proteins  103 
 
Chapter 6: G-substrate Interacting Proteins 
The role of phosphorylated G-substrate as a potent inhibitor of protein phosphatases is well 
documented (9,21). It is however unclear exactly what mechanisms are employed in 
performing this function and what other roles G-substrate plays in addition to phosphatase 
inhibition. Protein pull-downs from rat brain were employed to investigate G-substrate 
interacting proteins and provide valuable clues for the detection of its associated proteins in 
vivo. 
Pull-downs were performed according to the protocol described in „Materials and methods‟ 
section 2.12. Figure 6.1shows the image of a typical gel obtained from rat brain pull down 
experiments. 
In order to avoid chemical interaction of the rat brain proteins with excess reactive sites on the 
magnetic beads, BSA (in the case of tosylactivated beads) and ethanolamine (in the case of 
amine beads) were used to block excess active sites after beads were incubated with G-
substrate and before incubation with rat brain extract. 
Control experiments were performed by binding either BSA or ethanolamine to the relevant 
magnetic beads in the absence of G-substrate and carrying out the rat brain protein interaction 
steps identical to those employed for the G-substrate-bound beads (see section 2.12). Protein 
hits obtained for the G-substrate forms investigated were not reported if they were obtained 
for the control experiments as well. 
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Figure 6.1: SDS-PAGE of proteins pulled down by the different forms of G-substrate protein; 
 S=short, S-P=phospho-short, F/L=full length and P-F/L=phospho-full length. 
 
Protein hits obtained with the Mascot software (www.matrixscience.com) from peptides 
obtained from MALDI-tof mass spectroscopy are reported in Table 6.1. Reported proteins had 
MOWSE scores classified as „significant‟ with p<0.05, representing a less than 5 % chance 
that the observed match was a random event. The MOWSE score is a probability-based 
algorithm, which expresses the probability of protein matches being authentic as -10*log10 
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Table 6.1: Rat brain proteins pulled down by different forms of G-substrate. 
Molecular weight values shown under the different forms of G-substrate indicate the molecular weights at which the proteins were identified in the G-substrate 
pull down gels. 













SHORT          
G-
SUBSTRATE 
COMMENTS (FUNCTION, SUBCELLULAR 










58kDa - - - 
REGULATION OF CELL MORPHOLOGY AND CYTOSKELETAL 

















INVOLVED IN ANCHORING THE TERMINAL ACTIN 
FILAMENTS IN THE MYOFIBRIL TO THE MEMBRANE AND 
IN TRANSMITTING TENSION FROM THE MYOFIBRILS TO 
THE EXTRACELLULAR MATRIX NOT DETECTED IN BRAIN. 
NUCLEAR MITOTIC 
APPARATUS PROTEIN 1 
(238.2kDa) 
Q14980 - 25kDa - - - MAY BE A STRUCTURAL COMPONENT OF THE NUCLEUS. 
 
TITIN / CONNECTIN 
(3.816MDa) 
Q8WZ42 - 80kDa - - - KEY COMPONENT IN THE ASSEMBLY AND FUNCTIONING OF VERTEBRATE STRIATED MUSCLES. PHOSPHORYLATED 
UPON DNA DAMAGE, PROBABLY BY ATM OR ATR. 
MICROTUBULE-ASSOCIATED 
SER/THR PROTEIN KINASE 4 
(284.3kDa) 




Q07266 - 130kDa - 130kDa - BINDS F-ACTIN. DREBRINS MIGHT PLAY A ROLE IN CELL MIGRATION, EXTENSION OF NEURONAL PROCESSES AND 
PLASTICITY OF DENDRITES. 
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SHORT          
G-
SUBSTRATE 
COMMENTS (FUNCTION, SUBCELLULAR 
LOCATION, TISSUE-SPECIFIC EXPRESSION, 
ETC.) 
 
NON-MUSCLE MYOSIN 9 AND 
NON-MUSCLE MYOSIN 10 
(226.5kDa AND 229.0kDa ) 
P35579 
P35580 
- 180kDa 180kDa - 180kDa CELLULAR MYOSIN THAT APPEARS TO PLAY A ROLE IN CYTOKINESIS, CELL SHAPE, AND SPECIALIZED FUNCTIONS 




P18206 - 46kDa - - - ACTIN FILAMENT (F-ACTIN)-BINDING PROTEIN INVOLVED 





O76041 7kDa - - - - BINDS TO ACTIN AND PLAYS AN IMPORTANT ROLE IN THE ASSEMBLY OF THE Z-DISK. ISOFORM 2 MIGHT PLAY A 
ROLE IN THE ASSEMBLY OF FOCAL ADHESION. 
CONTACTIN-1 (113.3kDa) Q12860 100kDa 100kDa - - - MEDIATES CELL SURFACE INTERACTIONS DURING 
NERVOUS SYSTEM DEVELOPMENT. 
 
CYTOSPIN-A (124.6kDa) 
Q69YQ0 7kDa 18kDa - - - INVOLVED IN CYTOKINESIS AND SPINDLE ORGANIZATION. 




P06753 - - - 33kDa - BINDS TO ACTIN FILAMENTS IN MUSCLE AND NON-MUSCLE CELLS. 
 
DYNAMIN-1 (97.4kDa) 
Q05193 - - - - 88kDa MICROTUBULE-ASSOCIATED FORCE-PRODUCING PROTEIN 
INVOLVED IN PRODUCING MICROTUBULE BUNDLES AND 
ABLE TO BIND AND HYDROLYZE GTP. 
















ACTIN- AND MYOSIN-BINDING PROTEIN IMPLICATED IN 
THE REGULATION OF ACTOMYOSIN INTERACTIONS IN 
SMOOTH MUSCLE AND NONMUSCLE CELLS INVOLVED IN 












- - - EXPRESSED IN PROLIFERATING MYOBLASTS AND DIFFERENTIATED MYOTUBES. EXPRESSED IN MYOBLASTS, 
CARDIAC AND SKELETAL MUSCLES.HOMODIMER WHICH 
INTERACTS WITH MYOSIN. 
 
FILAMIN-A-INTERACTING 
PROTEIN 1 (137.7kDa) 
 
Q8K4T4 - - - - 29kDa BY ACTING THROUGH A FILAMIN-A/F-ACTIN AXIS, CONTROLS THE START OF NEOCORTICAL CELL MIGRATION 
FROM THE VENTRICULAR ZONE. MAY BE ABLE TO INDUCE 
DEGRADATION OF FILAMIN A. EXPRESSED IN MUSCLE. 
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SHORT          
G-
SUBSTRATE 
COMMENTS (FUNCTION, SUBCELLULAR 
LOCATION, TISSUE-SPECIFIC EXPRESSION, 
ETC.) 
 
CELL CYCLE PROTEINS 
CENTROSOMAL PROTEIN  
OF 112 kDa (112.7kDa) 




Q8CB73 15kDa - - - - CONTRIBUTES TO MITOTIC SPINDLE ASSEMBLY, MAINTENANCE OF CENTROSOME INTEGRITY AND 
COMPLETION OF CYTOKINESIS AS PART OF THE HAUS 
AUGMIN-LIKE COMPLEX. 
SYNAPTONEMAL COMPLEX 
PROTEIN 1 (114.2kDa) 
Q15431 65kDa 62kDa - - - MAJOR COMPONENT OF TRANSVERSE FILAMENTS OF 
SYNAPTONEMAL COMPLEXES, FORMED BETWEEN 
HOMOLOGOUS CHROMOSOMES DURING MEIOTIC 
PROPHASE. 
 
HEAT SHOCK PROTEIN  
HSP 90-BETA (83.3kDa) P08238 - 100kDa - - - 
MOLECULAR CHAPERONE THAT PROMOTES THE 
MATURATION, STRUCTURAL MAINTENANCE AND PROPER 
REGULATION OF SPECIFIC TARGET PROTEINS INVOLVED 






FAMILY MEMBER 10 
(118.8kDa) 





P04406 - 44kDa - - - HAS BOTH GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE AND NITROSYLASE ACTIVITIES, 
THEREBY PLAYING A ROLE IN GLYCOLYSIS AND 
NUCLEAR FUNCTIONS, RESPECTIVELY. 
PYRUVATE DEHYDROGENASE 







39kDa - - - 
THE PYRUVATE DEHYDROGENASE COMPLEX 
CATALYZES THE OVERALL CONVERSION OF PYRUVATE 
TO ACETYL-COA AND CO2. 
ALDEHYDE DEHYDROGENASE 





39.6kDa - - - IDENTIFIED AS AN UNDEREXPRESSED BIOMARKER OF TUMOUR AGGRESSIVENESS IN ASTROCYTIC TUMOURS. 
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200kDa - - - 







BINDING PROTEIN 2 (73.1kDa) 
Q92945 - 75kDa - - - PART OF A COMPLEX INVOLVED IN PRE-mRNA 
DOWNSTREAM CONTROL SEQUENCE (DCS). 
POLY [ADP-RIBOSE] 
POLYMERASE 14 (202.8kDa) 
Q460N5 - 58kDa - - - ENHANCES STAT6-DEPENDENT TRANSCRIPTION. 
ZINC FINGER PROTEIN 445 
(118.9kDa) 
P59923 - 23kDa - - - MAY BE INVOLVED IN TRANSCRIPTIONAL REGULATION. 
PIF1 DNA  
HELICASE 




42kDa - - - 
DNA-DEPENDENT ATPASE AND DNA HELICASE INHIBITING 
TELOMERASE ACTIVITY BY UNWINDING DNA/RNA 
DUPLEX FORMED BY TELOMERASE RNA AND TELOMERIC 
DNA IN A 5' TO 3' POLARITY. 
DNA REPAIR PROTEIN SWI5 
HOMOLOGUE (10.3kDa) 


















PROBABLE COMPONENT OF PROTEIN COMPLEX EIF4F, 
INVOLVED IN RECOGNITION OF mRNA CAP, ATP-
DEPENDENT UNWINDING OF 5'-TERMINAL SECONDARY 
STRUCTURE AND mRNA RECRUITMENT TO RIBOSOME. 
THOUGHT TO BE A FUNCTIONAL HOMOLOGUE OF 
EIF4G1. 
THIOREDOXIN DOMAIN-





25kDa - - - MAY BE REQUIRED FOR POST-TRANSLATIONAL MODIFICATION OF PROTEINS REQUIRED FOR 
ACROSOMAL BIOGENESIS. 
NUCLEOLAR  














CAN UNWIND DOUBLE-STRANDED RNA (HELICASE) AND 
CAN FOLD OR INTRODUCE A SECONDARY STRUCTURE TO 
A SINGLE-STRANDED RNA (FOLDASE). FUNCTIONS AS 
COFACTOR FOR JUN-ACTIVATED TRANSCRIPTION 
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SUBSTRATE 
COMMENTS (FUNCTION, SUBCELLULAR 
LOCATION, TISSUE-SPECIFIC EXPRESSION, 
ETC.) 
CYTOPLASMIC DYNEIN I  














ACTS AS A MOTOR FOR THE INTRACELLULAR RETROGRADE 
MOTILITY OF VESICLES AND ORGANELLES ALONG 
MICROTUBULES. 
DEFECTS IN DYNC1H1 ARE THE CAUSE OF SPINAL MUSCULAR 
ATROPHY, LOWER EXTREMITY, AUTOSOMAL DOMINANT 
(SMALED) AND CHARCOT-MARIE-TOOTH DISEASE TYPE 2O 
(CMT2O). 
CYTOPLASMIC 
DYNEIN 2  













MOTOR FOR INTRAFLAGELLAR RETROGRADE TRANSPORT. 
DEFECTS IN DYNC2H1 ARE THE CAUSE OF ASPHYXIATING 
THORACIC DYSTROPHY TYPE 3 (ATD3) AND SHORT RIB-
POLYDACTYLY SYNDROME TYPE 3 (SRPS3). 
ZINC FINGER CCCH DOMAIN-














PHOSPHORYLATED UPON DNA DAMAGE, PROBABLY BY 
ATM OR ATR. 





















HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN 
(HNRNP) IMPLICATED IN mRNA PROCESSING 
MECHANISMS. 
HISTONE H1OO(OOCYTE-














MAY PLAY A KEY ROLE IN THE CONTROL OF GENE 
EXPRESSION DURING OOGENESIS AND EARLY 
EMBRYOGENESIS, PRESUMABLY THROUGH THE 
















INVOLVED IN REGULATING AMPA RECEPTOR 
TRAFFICKING IN THE CENTRAL NERVOUS SYSTEM IN AN 
NMDA-DEPENDENT MANNER. ENHANCES ANDROGEN 
RECEPTOR (AR)-MEDIATED TRANSCRIPTION. 
NUCLEOSOME ASSEMBLY 




50kDa - - - - 
MAY BE INVOLVED IN MODULATING CHROMATIN 
FORMATION AND CONTRIBUTE TO REGULATION OF CELL 
PROLIFERATION. 
 





Q9QUL6 - - 
 
150kDa - - REQUIRED FOR VESICLE-MEDIATED TRANSPORT. CATALYZES THE FUSION OF TRANSPORT VESICLES WITHIN 
THE GOLGI CISTERNAE. 
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REGULATION OF SYNAPTIC VESICLE DOCKING AND 
FUSION, POSSIBLY THROUGH INTERACTION WITH GTP-
BINDING PROTEINS. ESSENTIAL FOR 
NEUROTRANSMISSION AND BINDS SYNTAXIN, A 
COMPONENT OF THE SYNAPTIC VESICLE FUSION 
MACHINERY. 














MOTOR REQUIRED FOR THE RETROGRADE TRANSPORT 
OF GOLGI VESICLES TO THE ENDOPLASMIC RETICULUM. 
HAS A MICROTUBULE PLUS END-DIRECTED MOTILITY. 
BREFELDIN A-INHIBITED 
GUANINE NUCLEOTIDE-














PROMOTES GUANINE-NUCLEOTIDE EXCHANGE ON ARF1, 
ARF5 AND ARF6. PROMOTES THE ACTIVATION OF 
ARF1/ARF5/ARF6 THROUGH REPLACEMENT OF GDP WITH 
GTP. DEFECTS IN ARFGEF2 ARE THE CAUSE OF 
AUTOSOMAL RECESSIVE PERIVENTRICULAR NODULAR 
HETEROTOPIA TYPE 2 (PVNH2). 
 
GTP RELATED PROTEINS 
 
G-PROTEIN-REGULATED 
INDUCER OF NEURITE 














MAY BE INVOLVED IN NEURITE OUTGROWTH. 
WIDELY EXPRESSED IN THE CENTRAL NERVOUS SYSTEM, 
WITH HIGHEST LEVELS IN SPINAL CORD. 
















ACTIVATES CDC42, A MEMBER OF THE RAS-LIKE FAMILY 
OF RHO- AND RAC PROTEINS, BY EXCHANGING BOUND 
GDP FOR FREE GTP. PLAYS A ROLE IN REGULATING THE 





Q9JHZ4 - - 
 
170kDa - - 
INTERACTS WITH GRIP1, GRIP2 AND AMPA RECEPTORS. 
PROTEOLYTICALLY CLEAVED BY CASPASE-3. 
RAB GTPASE-BINDING  














RAB EFFECTOR PROTEIN ACTING AS LINKER BETWEEN 
GAMMA-ADAPTIN, RAB4A AND RAB5A. PROTEOLYTIC 
CLEAVAGE BY CASPASES IN APOPTOTIC CELLS CAUSES 
LOSS OF ENDOSOME FUSION ACTIVITY. 
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MAY INDUCE BOTH CASPASE-DEPENDENT APOPTOSIS 
AND CASPASE-INDEPENDENT CELL DEATH. DETECTED IN 
SEVERAL TUMOUR CELL LINES. 
 
PROTEIN KINASE C 













REGULATION OF MULTIPLE CELLULAR PROCESSES LINKED 
TO CYTOSKELETAL PROTEINS. NEURON GROWTH AND 
ION CHANNEL REGULATION.  INVOLVED IN IMMUNE 
RESPONSE, CANCER CELL INVASION REGULATION OF 
APOPTOSIS AND WOUND HEALING. 
ACYLPHOSPHATASE 2 
(11kDa) 




PHYSIOLOGICAL ROLE NOT YET CLEAR. 
 













ONCOPROTEIN THAT INHIBITS PP2A AND STABILIZES MYC 
IN HUMAN MALIGNANCIES. PROMOTES ANCHORAGE-
INDEPENDENT CELL GROWTH AND TUMOUR 
FORMATION. 
MITOGEN ACTIVATED 
PROTEIN KINASE KINASE 














MEDIATES ACTIVATION OF THE NF-KAPPA-B, AP1 AND 
DDIT3 TRANSCRIPTIONAL REGULATORS. (ACTIVATED BY 
PHOSPHORYLATION ON THR-530). 
 
UBIQUITIN RELATED PROTEINS 
 
UBIQUITIN CARBOXYL-














FUNCTIONS TO PROCESS NEWLY SYNTHESIZED 
UBIQUITIN, TO RECYCLE UBIQUITIN MOLECULES OR TO 
EDIT POLYUBIQUITIN CHAINS AND PREVENTS 
PROTEASOMAL DEGRADATION OF SUBSTRATES. 
 














E3 SUMO-PROTEIN LIGASE WHICH FACILITATES SUMO1 
AND SUMO2 CONJUGATION BY UBE2I. SPECIFIC DOCKING 
SITE FOR THE NUCLEAR EXPORT FACTOR EXPORTIN-1. 
INTERACTS WITH PARK2 
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INTRACELLULAR CHANNEL THAT MEDIATES CALCIUM 
RELEASE FROM THE ENDOPLASMIC RETICULUM 
FOLLOWING STIMULATION BY INOSITOL 1,4,5-
TRISPHOSPHATE. DEFECTS CAUSE SPINOCEREBELLAR 
ATAXIA 15. 
BARDET-BIEDL  






- - - PROBABLE EFFECTOR OF THE PLANAR CELL POLARITY 
SIGNALLING PATHWAY WHICH REGULATES THE SEPTIN 
CYTOSKELETON IN BOTH CILIOGENESIS AND COLLECTIVE 
CELL MOVEMENTS DEFECTS IN THIS PROTEIN ARE THE 
CAUSE OF BARDET-BIEDL SYNDROME TYPE 15 (BBS15). 
EPHRIN TYPE-A  
RECEPTOR 7 (112kDa) 
P54759 - 36kDa - - - RECEPTOR TYROSINE KINASE WHICH BINDS 
PROMISCUOUSLY GPI-ANCHORED EPHRIN-A FAMILY 
LIGANDS RESIDING ON ADJACENT CELLS, LEADING TO 

















PROTEIN 22) (22.5kDa) 
P37805 - - - - 
 
22.5kDa MEMBER OF THE CALPONIN PROTEIN FAMILY. INVOLVED 
IN THE REGULATION OF NEURITE GROWTH. INTERACTS 
WITH F-ACTIN. 
LINE-1 TYPE TRANSPOSASE 
DOMAIN-CONTAINING 






























MAY BE INVOLVED IN WOUND HEALING PATHWAY 
UNDERLYING THE FAVOURABLE EARLY WOUND CLOSURE 
CHARACTERISTICS OF ORAL MUCOSA. 
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FUNCTIONS AS A CYSTEINE PROTEASE UPON CLEAVAGE 
OF A C-TERMINAL PEPTIDE. PROTECTS CELLS AGAINST 
OXIDATIVE STRESS AND CELL DEATH. 
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6.1 Proteins interacting with the G-substrate Isoforms 
Proteins interacting with phosphorylated and un-phosphorylated G-substrate isoforms 1 (full-
length) and 2 (short) as well as the G-substrate phospho-peptide (section 6.1.3) were 
investigated using pull-down assays and interacting proteins identified by MALDI-tof mass 
spectrometry. The proteins have, for the most part, MOWSE scores considered „significant‟ 
within a 5% error although interesting associations with proteins whose scores were 
considered „non-significant‟ are also mentioned. Molecular weights of some of the proteins 
corresponded to the appropriate sizes on the polyacrylamide gels used although in most cases 
bands at lower molecular weights, which most likely represent fragments of the identified 
proteins, were encountered. In a few cases proteins identified using the Mascot software were 
of molecular masses lower than the molecular weights at which their corresponding bands ran 
on the pull-down gels. One possible reason for such observations is the fact that some 
proteins, like G-substrate, run anomalously on SDS-PAGE. Each protein has been assigned a 
functional group in the table above based on its most significant function or associated 
pathway although a number of the proteins fall into more than one of the categories shown. 
Based on the identity of proteins pulled down, G-substrate is potentially involved in processes 
including apoptosis, the maintenance of the cytoskeleton/cell structure, cell cycle control, 
regulation of transcription and translation, endocytosis and cellular metabolism. 
 
6.1.1 G-substrate Isoform 1 
In addition to providing the largest proportion of putative interacting proteins, full-length G-
substrate was the only form of the protein that pulled down proteins involved in metabolism, 
ion-transport and signalling. From the results only three proteins were pulled down by both 
full length and short G-substrate – the 77kDa developmentally-regulated brain protein 
(Drebrin) and non-muscle myosins 9 and 10. The cellular myosin is thought to play a role in 
secretion and capping as well as cytokinesis and the maintenance of cell shape while the F-
actin-binding drebrin is implicated in dendritic plasticity, cell migration and the extension of 
neural processes. Interestingly, full-length, short G-substrate and the phosphopeptide all 
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pulled down distinct actin-binding proteins as well, suggesting in vivo interactions with actin 
for both isoforms of G-substrate, both phosphorylated and unphosphorylated.  
 
6.1.2 G-substrate Isoform 2 
Compared with full length G-substrate, short G-substrate pulled down fewer proteins, perhaps 
due to the fact that the full length protein is much more abundant than the short isoform. The 
main unique interactions observed for short G-substrate were with proteins associated with 
the cytoskeleton and cellular structure including the motor protein dynamin and the F-actin-
binding alpha-3 chain of tropomyosin.  
 
6.1.3 Proteins Interacting with G-substrate Phosphopeptide 
In order to adequately investigate interactions involving phosphorylated G-substrate isoforms, 
which potentially directly involve the phosphorylation motif, pull-downs were performed with 
the G-substrate phosphopeptide CDQKKPRRKD[pT]PAL-amide (where pT is a 
phosphorylated threonine), coupled to magnetic beads. The phosphopeptide was coupled to 
the magnetic beads at its N-terminus (using the cysteine residue) in order to avoid masking 
the phosphorylated threonine residue. Proteins pulled down uniquely by the peptide were 
involved in the maintenance of centrosome integrity and completion of cytokinesis, mRNA 
cap recognition and mRNA recruitment to the ribosome. The DUSTY protein kinase, whose 
role in programmed cell death is discussed below, was also pulled down by the peptide, 
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6.2 Discussion 
A number of proteins pulled down possess similar domains and / or are implicated in a 
common cellular process. A few of these interesting associations are discussed in the 
following paragraphs. 
 
6.2.1 Intracellular Vesicle Transport 
The possibility of an interaction between G-substrate and the IP3 receptor, which is located on 
the endoplasmic reticulum of the Purkinje cells, may be further supported by the observation 
that interactions seem to exist between G-substrate and other proteins involved in intracellular 
vesicle transport, possibly involving the endoplasmic reticulum. Full length G-substrate 
pulled down the vesicle-fusing ATPase, which is required for transport mediated by vesicles 
and is also a catalyst for the fusion of transport vesicles inside the cisternae. A number of 
proteins involved in vesicle activity were also pulled down by full length G-substrate. These 
included the kinesin-like protein KIF1C and the heavy chains of cytoplasmic dyneins 1 and 2, 
all of which function primarily as motors for vesicle motility. Defects in the heavy chain of 
cytoplasmic dynein 1 have been associated with dominant spinal muscular atrophy (78) as 
well as severe intellectual disability and defects in neuronal migration (79) Defects in the 
heavy chain of cytoplasmic dynein 2, which is important for the generation and maintenance 
of cilia (80) is associated with asphyxiating thoracic dystrophy type 3 (ATD3) and short rib-
polydactyly syndrome type 3 (SRPS3). Mutations in both dynein and kinesin proteins have 
been shown to result in a reduction of the Sonic hedgehog (Shh) signalling pathway, which is 
important for the growth and patterning of brain structures during development (81) The Shh 
pathway has also been found to play an essential role in neurite outgrowth, a process in which 
contactin-1 and GRIN-1 (both pulled down by both full length G-substrate and the G-
substrate peptide) are involved.  
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6.2.2 Cerebellar Long Term Depression 
Cerebellar long-term depression (LTD) is thought to be the cellular mechanism for cerebellar 
motor learning (51) and involves a reduction in the efficacy of neuronal synapses over time. It 
has been suggested that G-substrate plays a role in the regulation of LTD induction in 
Purkinje cells as part of the NO/cGMP/PKG pathway (10). Evidence from several 
experiments also suggest that the IP3/Ca
2+
 pathway is responsible for LTD (82,83) although 
the details remain largely unresolved. The fact that the opening of the IP3 receptor and the 
induction of LTD require a similar set of input signals may provide further insight into the 
process - the opening of the IP3 receptor channel depends on the simultaneous presence of IP3 
and calcium, while the induction of LTD requires the detection of a near simultaneous arrival 
of synaptic inputs from the climbing fibres (resulting in the generation of a calcium signal) 
and the parallel fibres (activation of metabotropic receptors to produce IP3) by the Purkinje 
neuron (84). The observation that the G-substrate phosphopeptide pulled down the IP3 
receptor provides further support for the involvement of these two proteins in LTD. 
Interestingly, the most abundant expression of G-substrate is in cerebellar Purkinje cells, 
which places it at the right location for participation in this process. The observation that the 
IP3 receptor was pulled down by the G-substrate peptide suggests that interaction with the IP3 
receptor in humans could be with the phospho-forms of either full length or short G-substrate 
or even both isoforms since both isoforms possess the same phosphorylation motif with the 
only difference being that full length G-substrate possesses two while short G-substrate 
possesses one. The absence of interaction with the same receptor in pull-downs performed 
with the phospho- forms of both isoforms might be due to the fact that analyses with the 
peptide were performed to ensure the orientation of the phosphopeptide such that it was 
completely unobstructed and available for interaction while the possibility exists that although 
of identical structure, the phosphorylation motifs in the intact proteins might have been less 
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6.2.3  Inositol Triphosphate Signalling  
G-substrate has been implicated in several diseases including hypercholesterolemia (28) and 
Parkinson‟s disease (PD) because it is possibly involved in a number of pathways that are 
important in maintaining proper cellular function. It has been known for several years that G-
substrate is part of the NO-sGC-cGMP-PKG pathway but results showing a possible 
interaction of full length G-substrate with IP3R1 suggests an additional role in the IP3 
pathway, which is important for the maintenance of calcium homeostasis and has been linked 
to several diseases including spinocerebellar ataxia type 1 (SCA 1), Huntington‟s disease and 
Alzheimer‟s. The role of calcium signalling in Alzheimer‟s disease (AD) (85) is reinforced by 
the fact that mutations in the genes for presenilins 1 and 2 and in the amyloid precursor 
protein (APP) gene, all resulting in abnormal signalling in the endoplasmic reticulum, have 
been strongly linked to familial AD. In addition, the use of calcium channel blockers in the 
treatment of AD has resulted in some success (86). One important role of the IP3 signalling 
pathway is the activation of PKC, a serine threonine kinase whose activation can involve both 
DAG and the increase in intracellular Ca
2+
 stimulated by the binding of IP3 to its receptor 
(Figure 6.2). PKC can also be activated by limited proteolysis with calpain to produce a 
smaller component, which is enzymatically active completely independently of Ca
2+
, 
phospholipid or DAG. Membrane-bound PKC is thought to be more susceptible to this 
proteolysis than soluble PKC (87). Interestingly, G-substrate is also proteolytically cleaved by 
calpain and it has been suggested that the calpain-mediated degradation of G-substrate 
represents an important mechanism contributing to NMDA-induced amacrine cell death (88). 
Interaction of G-substrate with IP3R1 is of great interest because both proteins have been 
found to show altered expression in SCA1 transgenic mouse models with G-substrate mRNA 
being significantly down regulated (64). 
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Figure 6.2: Protein kinase C regulation. 
PIP2= phosphatidylinositol-4,5-bisphosphate, PLC=phospholipase C, IP3=inositol triphosphate, DAG=diacyl 
glycerol, ER=endoplasmic reticulum, PKC=protein kinase C. 
 
Interaction of G-substrate with proteins located on or associated with the endoplasmic 
reticulum (in this case IP3R1) is supported by the observation that G-substrate contains a 
possible endoplasmic reticulum membrane retention signal – a „KKXX-like‟ motif 
represented by the sequence DKIA in the C-terminal region and one of two peroxisomal 
targeting signals (PTS2) within the sequence --- KLDPRCSHL--- located near its N-terminal 
region. Both of these putative localization signals occur outside the section missing from the 
short protein. This implies that the possibility of interaction with the endoplasmic reticulum 
and peroxisomes exists for both isoforms of human G-substrate. Peroxisomes are derived 
from the endoplasmic reticulum and function mainly in the oxidation of long chain fatty acids 
in humans (89). The observation that G-substrate interacts with glyceraldehyde-3-phosphate 
dehydrogenase, another protein associated with peroxisomes, further strengthens the argument 
for association of G-substrate with peroxisomes. 
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6.2.4 The Pleckstrin Homology Domain 
The production of the phosphatidylinositols (PtdIns) PtdIns-3,4,5-trisphosphate and PtdIns-
3,4-bisphosphate leads to the recruitment of proteins containing the pleckstrin homology 
domain to the plasma membrane. The pleckstrin homology (PH) domain is an approximately 
100 amino acid domain that occurs in a wide range of proteins involved in cytoskeletal 
structure and intracellular signalling. The domain has been found in over 40 proteins 
including protein kinases, phospholipases, guanine nucleotide exchange factors and 
cytoskeletal proteins. Although the function of this domain is not known for sure, it has been 
suggested that it could include binding to lipids, phosphorylated serine/threonine residues and 
the  subunits of heterotrimeric G-proteins.  
The G-substrate protein pull-downs resulted in the identification of three proteins involved 
with/or possessing the PH domain. Considering information about putative binding partners, 
dynamin, which was pulled down by phospho-short G-substrate, could possibly be interacting 
with the phosphorylated threonine residue of G-substrate via its PH domain. Since full length 
G-substrate protein possesses two such phosphorylated threonine residues within similar 
phosphorylation motifs, it is possible that the phosphorylated full length protein might also 
interact with dynamin. The absence of identified interactions of the full length protein with 
dynamin could be a result of the interaction preferring the presence of only one phospho-
threonine residue (as seen in phospho-short G-substrate). Full length G-substrate pulled down 
the Ras-like family member protein FYVE, RhoGEF and PH domain containing protein 4 
(Protein 4) and the kinesin-like protein KIF1C, which functions in the retrograde transport of 
golgi vesicles to the endoplasmic reticulum.  Protein 4 is thought to activate cell division 
control protein 42 (CDC42), a member of the Ras-like family of Rho- and Rac proteins, by 
exchanging bound GDP for free GTP and also activate the stress-activated protein kinase 
JNK1 (JNK1) via CDC42. Protein 4 also binds to phosphatidylinositols (PtdIns) (PtdIns-4,5-
bisphosphate, PtdIns-3,4,5-trisphosphate, PtdIns-5-monophosphate, PtdIns-4-monophosphate 
and PtdIns-3-monophosphate). 
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6.2.5 Apoptosis 
Eight proteins involved in the apoptotic process or cleaved by caspases were pulled down by 
G-substrate; five of them, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Rab 
GTPase effector protein 1 (Rabatin), heat shock protein HSP 90-beta (HSP 90-B), E3 sumo-
protein ligase RanBP2 and Huntingtin-interacting protein 1 (HIP-1), were pulled down by full 
length G-substrate. Protein kinase C epsilon (PKCε) and grip1-associated protein 1 (GRAP-1) 
were both pulled down by phosphorylated full length G-substrate and the dual 
serine/threonine tyrosine protein kinase (DUSTY protein kinase) was pulled down by the G-
substrate phospho-peptide. These three proteins can, therefore, be said to interact with 
phosphorylated (full length) G-substrate with DUSTY protein kinase possibly interacting with 
the phosphorylation motif. Five of these proteins have been described as caspase substrates; 
Rabatin and GRAP-1 are cleaved by caspase-3 and GAPDH and HSP 90-B by caspase-6. 
RanBP2 has been shown to possess a putative caspase cleavage site using proteomic methods 
(90). HIP-1, via its caspase-dependent death effector domain, is involved in the induction of 
apoptosis (91) while DUSTY protein kinase plays a part in the induction of both caspase-
dependent and caspase-independent apoptosis. Zha and co-workers (92) showed that the 
overexpression of the protein in Hek 293 cells induced DNA fragmentation, which is 
considered a hallmark of caspase-dependent apoptosis. The absence of inhibition of DUSTY 
protein kinase induced cell death morphology in the presence of the pan-caspase inhibitor 
VAD-fmk led the researchers to suggest the involvement of DUSTY protein kinase in a 
second caspase-independent apoptotic pathway.  
In addition to being a substrate for caspase-6 during apoptosis, GAPDH, when S-nitrosylated 
in response to oxidative stress forms a complex with Siah-1, an E3 ubiquitin ligase. This 
SNO-GAPDH : Siah1 complex is subsequently translocated to the nucleus where it induces 
apoptosis by the ubiquitination and degradation of nuclear proteins in a process independent 
of GAPDH glycolytic activity (93). 
PKCε has been shown to inhibit caspases-8 and -9, which contribute substantially to the 
induction of proteolytic cascades essential for the effective execution of apoptosis in cells 
marked for death. Jabůrek and co-workers (94) confirmed the co-localization of PKCε and the 
ATP-sensitive mitochondrial channel mitoKATP on the mitochondrial inner membrane and 
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described a functional association between the two proteins reportedly present in rat liver, 
heart and brain. The pull-down of PKCε by phosphorylated G-substrate is particularly 
interesting because the NO/sGC/cGMP/PKG pathway (described in 6.2.3) has been shown to 
influence the opening of mitoKATP on the mitochondrial inner membrane, leading to swelling 
of the mitochondrial matrix and the generation of reactive oxygen species. The detection of 
PKCε as a possible interacting partner of phosphorylated G-substrate suggests involvement of 
phospho-G-substrate in the signal transduction process that regulates the opening of the 
mitoKATP channel. The observation that PP2A, known to be effectively inhibited by phospho-
G-substrate reverses the PKCε-dependent opening of mitoKATP (95) strengthens the 
possibility of G-substrate involvement in this process. This may provide more insight into the 
mechanism by which G-substrate overexpression works to protect A9 DA cells from PD 
toxins, since oxidative stress is a major hallmark of PD. Deficiency in the cysteine protease 
DJ-1, also known as PARK7, has been shown to sensitize dopaminergic neurons to stress-
mediated apoptosis in hereditary Parkinson‟s disease. DJ-1 was detected in pull-downs 
performed with short G-substrate. Western blot analysis using antibodies specific for DJ-1 
was performed on G-substrate pull-downs to further investigate DJ-1 association with G-
substrate (Figure 6.3). DJ-1 was identified in the rat brain pull-downs with phosphorylated 
short G-substrate and unphosphorylated full length G-substrate rat brain pull-downs. 
Although a fainter band was obtained around the same molecular weight for the control pull-
downs, the absence of interaction with the other forms of G-substrate and the fact that 
interaction was observed between G-substrate and DJ-1 in vitro suggested that the observed 
interaction was worthy of further study. 
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Figure 6.3: Western blot image showing rat brain pull-downs obtained for different forms of G-substrate 
protein probed with an antibody raised against DJ-1. 
 
The possibility of interaction between G-substrate and DJ-1 is very intriguing since both of 
these proteins have been linked with neuroprotection in PD. Since DJ-1 has been linked with 
reactive oxygen species (ROS) damage (96). The pull-down by G-substrate of the IP3R1 
protein, which is localized in the MIM and plays a role in the control of ROS metabolism 
among other things hints at the tantalizing possibility of exploiting a possible interaction 
between G-substrate and DJ-1 in the development of interventions for treatment for PD and 
similar neurodegenerative conditions.  
 
6.3 Cancer/Tumour Growth 
Work by Rodriguez and co-workers identified the aldehyde dehydrogenase family 1 member, 
ALDH1L1, as an under expressed biomarker of tumour aggressiveness in astrocytic tumours 
(97). ALDH1L1, which was pulled down by full length G-substrate, is involved in folate 
metabolism and catalyses the conversion of 10-formyltetrahydrofolate (10-FTHF) to 
tetrahydrofolate. ALDH1L1 is thought to play a regulatory role in cell proliferation (98) and 
expression of ALDH1L1 in neural tubes correlates with a reduction of cellular proliferation.  
Full length G-substrate also pulled down Huntingtin-interacting protein 1 (HIP-1), which is 
involved in regulating AMPA receptor trafficking in the central nervous system in an NMDA-
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dependent manner. In addition to determining the severity of Huntington‟s disease by its 
interaction with Huntingtin protein, Hip-1 is up-regulated in prostate and colon cancers. 
Work by Jianbin Peng and co-workers using tumour cell lines found DUSTY protein kinase, 
which was pulled down in this study by the G-substrate peptide, downregulated in tumours of 
breast, ovary, lung and pancreas (99). 
The G-substrate peptide also pulled down the “cancerous inhibitor of PP2A” (CIP2A). CIP2A 
interacts directly with the oncogenic transcription factor c-Myc and inhibits PP2A-mediated 
MYC dephosphorylation and proteolytic degradation (42). CIP2A is also known to promote 
anchorage independent cell growth and in vivo tumour formation (100). The fact that CIP2A 
was pulled down by phosphopeptide, which represents the form of G-substrate involved in 
PP2A, is interesting and might provide clues for the mechanism of phosphatase inhibition by 
phospho G-substrate. 
DJ-1/Park7 expression is significantly increased in cancer compared to normal tissue and its 
overexpression has been observed in many cancers including breast, lung, pancreatic, ovarian, 
and prostate (101). DJ-1 is a negative regulator of the tumour suppressor, PTEN which 
functions as a dual specificity protein and lipid phosphatase (102). PTEN shows a substrate 
preference for inositides of PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4 and 
its lipid phosphatase activity is thought to be critical for its function as a tumour suppressor 
(103). 
 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 6 G-substrate Interacting Proteins  125 
 
6.4 G-substrate Interactome 
 
Figure 6.4: G-substrate „interactome‟ modified from “string” (string-db.org) 
 
A search using the online tool „string‟ (http://string-db.org/), which attempts to bring together 
all known interactions for a query protein, yielded an „interactome‟ (Figure 6.4) for G-
substrate protein, which contained associations with catalytic and regulatory subunits of PP2A 
and a regulatory subunit of PP1. Interactions were also shown for PKA and PKG. It is worth 
noting that although isoform 1 has been shown as the documented interacting partner for G-
substrate, PKG2 is the brain specific isoform of this kinase. Interactions are also reported for 
thrombospondin 1, cathepsin G and the ankyrin repeat containing protein KRIT1, whose gene 
is located on the same chromosome (chromosome 7) as G-substrate and plays an important 
role in the maintenance of intracellular ROS homeostasis and apoptosis. 
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Based on the cellular processes discussed above, Figure 6.5 summarises the novel interactions 
observed for G-substrate protein in this study. 
  
 
Figure 6.5: Summary diagram showing some novel G-substrate interacting proteins and the processes 
with which they are involved.   
Processes/pathways are represented by rectangles and proteins by circles or ellipses. (See Table 6.1 for 
abbreviations).
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The use of in-gel tryptic digestion of SDS-PAGE bands followed by mass spectrometry 
resulted in successful identification of proteins pulled down by G-substrate. In some cases 
confirmation of protein identity was achieved using western blotting with antibodies specific 
to the protein of interest. 
It is possible in some instances that the protein pulled down might be interacting with G-
substrate indirectly, if it is a direct interacting partner of another protein. In this case 
reciprocal pull-downs, which involve pulling down proteins from a similar sample of rat brain 
extract with the identified protein followed by western blot analysis of the pull-down proteins 
with antibodies specific to the original protein, would possibly confirm the interaction in vivo 
of the two proteins. 
Nevertheless, even if some of the proteins listed in Table 6.1are indirect partners of the 
various G-substrate constructs, their identification indicates potential functional involvement 
in a protein complex (Figure 6.5). 
The Mascot software used to analyse the data obtained from MALDI-tof mass spectrometry 
was able to identify instances where more than one protein was present in a single band and 
classified these as mixtures. Where logistically possible, the use of 2D SDS-PAGE to separate 
interacting proteins obtained from pull-down experiments would result in the separation of 
proteins with similar molecular weights on the gel and potentially result in more accurate 
identification of the proteins pulled down. 
In addition to the methods used in this work, protein-protein interactions can be observed in 
vivo by fusing the proteins of interest to fluorescent proteins including the green fluorescent 
protein (GFP) and its colour variant mutants and co-transforming these proteins into cell lines. 
The interactions of the proteins of interest can then be observed using fluorescence resonance 
energy transfers (FRET). This method, in addition to allowing the observation of protein 
interactions, also makes it possible to determine the subcellular localizations of such 
interactions and thereby shed more light on the protein‟s functions in vivo. 
The criteria for deciding whether such protein interactions are authentic are reviewed in 
Mackay et al (104). The article also critically reviews the methodology and table 1 in the 
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review has an overview of detection limits. The authors suggest that the “gold standard” 
criterion for reliability in the Molecular Interactions Database (MINT; 
http://mint.bio.uniroma2.it/mint/) is the existence of co-immunoprecipitation data, which 
presumes the availability of antibodies specific for all the identified proteins. This is disputed 
by the curators of “Mint” who suggest that confidence should be built on the integration of all 
evidence from several experimental approaches (105)  
In another article commenting on the Mackay et al review, Welch (106) states that “it must be 
borne in mind that the protein-interaction mapping for a given cell-type – even when obtained 
under the most reliable of experimental conditions – represents a relative and variable thing. 
As trite as it might be to say, the interactome (like all „omes‟ downstream from the genome) is 
a dynamic entity, the structure-and-function of which is constantly subject to intra- and extra-
cellular physiological influences. Pre-genomic systems biology has made it all too evident 
that the interactome is an observationally „fuzzy‟, yet seductively attractive, object of 
curiosity.” 
The notion of “fuzziness” is also discussed by Tompa and Fuxreiter (107) who found 
“significant structural disorder or polymorphism” in protein-protein interactions. The 
presence of dynamism in the composition and interaction of protein complexes most likely 
confers adaptability, versatility and reversibility on protein-protein interactions. Discoveries 
such as this call for a revision of the methods currently used in the study of such interactions 
and the inferences that can be drawn from the results of such studies. 
The interactions observed in this study represent a first step following which several other 
methods can be applied to shed more light on the interactions and cellular functions of G-
substrate. 
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Chapter 7: G-substrate, DJ-1 and Tanganil 
The human PARK7/DJ-1 gene is located on chromosome 1 and encodes a 189 amino acid 
protein, which is ubiquitously expressed (108)and particularly abundant in cerebral tissues 
(109). DJ-1 belongs to the ThiJ/PfpI family whose members contain a conserved domain and 
are involved in a wide range of molecular processes including regulation of RNA-protein 
interaction, proteolysis and chaperoning. DJ-1 has been linked to a number of physiological 
processes including sperm fertilization (110) regulation of RNA-protein interaction (111) and 
oxidative stress response (112-114). 
 
7.1 DJ-1 in Parkinson’s disease 
The 10-15 % of PD cases that are not sporadic have been associated with a variety of loss-of-
function mutations in genes including α-synuclein, parkin, PINK1, dardarin /leucine-rich 
repeat kinase 2 (LRRK2) and DJ-1/PARK7.  
DJ-1 is associated with several important neuroprotective roles including transcriptional 
modulation, oxidative stress sensing and guarding of mitochondrial function. DJ-1 is also 
involved in apoptosis inhibition by suppressing apoptosis signalling kinase 1 (ASK1) and 
death protein Daxx while simultaneously supporting the pro survival Akt pathway. In 
addition, DJ-1 has been found to function as a molecular chaperone to prevent heat-induced 
aggregation of α-synuclein (SNCA). Although these are diverse roles, they have the net result 
of opposing apoptosis associated with oxidative stress as is found in PD. Although oxidative 
stress alone can lead to neuronal death, it also triggers mitochondrial dysfunction and 
impairment of the ubiquitin-proteasome system, which further aggravates nigral pathology 
(115). Because of the tight interconnection of these factors, initiation of one inevitably 
recruits the others to participate in events that ultimately result in situations similar to the 
pathogenesis of PD. The fact that defects in the gene encoding DJ-1 have been identified as 
the cause of autosomal recessive juvenile early-onset Parkinson disease 7 underscores the 
importance of functional DJ-1 to cell survival. Although Parkinsonism caused by this 
mutation is very rare, DJ-1 is the second most frequent identifiable genetic causes of PD, after 
parkin/PARK2 (116). 
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Neurons of the substantia nigra pars compacta (SNc) are the cells most affected by PD and 
particularly susceptible to oxidative stress as a result of a higher basal oxidative stress 
resulting from „mitochondrial flickering‟. „Mitochondrial flickering‟ refers to a phenomenon 
involving the transient spontaneous depolarization of mitochondria. This phenomenon 
induces oxidative stress because the Ca
2+
 ions which enter during depolarization are removed 
using ATP generated by oxidative phosphorylation in the mitochondria. The high basal 
oxidative stress endured by the SNc neurons explains their particular sensitivity to hikes in 
oxidative stress due to conditions like PD. A role in sensing and protecting neurons from 
reactive oxygen species (ROS) will undoubtedly make active, functional DJ-1 indispensable 
to these neurons. In addition, DJ-1‟s prospective role in assisting protein refolding will ensure 
that any unfolded/misfolded proteins resulting from such cellular stress which may aggregate 
and stimulate neuronal pathology would be refolded, extending the lives of these neurons. 
 
7.2 DJ-1 Structure  
X-ray crystallography revealed that DJ-1consists of eight α-helices and eleven β-sheets and 
adopts a flavodoxin-like Rossmann fold. DJ-1 possesses structural homology to the bacterial 
PfpI/PH1704 proteases (117) with an additional α helix at the C- terminus of the protein, 
which projects away from the remainder of the structure and prohibits access to the active site 
binding pocket Investigations using size exclusion chromatography and dynamic light 
scattering showed that DJ-1 exists mainly as a dimer (Sun-Joo Lee et. al., 2003) with two DJ-
1 monomers making extensive contacts covering about 35 % of the molecular surface of each 
molecule. The dimeric interactions in DJ-1 were found between the α1, α 7, and α 8 helices 
and the β4 strand from each monomer, with the interactions between the β4 strands forming 
an inter-molecular short sheet (Figure 7.1). A putative active site has been identified near the 
dimer interface, and the residues Cys-106, His-126, and Glu-18 may play important roles in 
catalysis by this protein. 
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Figure 7.1: Ribbon structure of DJ-1 
A: DJ-1 monomer - α-helices are in red; β-sheets in yellow; loops in green. B: DJ-1 monomer with C-terminal 
helix 8, which is cleaved to produce biologically active DJ-1, in blue (PDB accession: 1P5F). C: Dimer of wild 
type DJ-1 with monomers in red and blue. L166 is in green on both monomers and close to the putative dimer 
interface enclosed in orange rectangle. 
 
 
The leucine residue at position 166 has been found to be vital for DJ-1 dimerisation (116). 
This residue is highly conserved among DJ-1 homologues, suggesting that dimerisation is 
central to the biological function(s) of this protein. A point mutation that replaces the leucine 
residue at position 166 with proline has been shown to predispose patients in consanguineous 
Italian families to early onset Parkinsonism (116) L166P is a loss of function mutation which 
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is likely due to the proline residue disrupting the structure of helix 7, within which L166 is 
located, leading to misfolding and subsequent loss of protein activity. Several groups have 
predicted that the protein dysfunction results from failure of L166P DJ-1 to form homodimers 
or heterodimers with wild-type DJ-1, however Baulac and coworkers (118) showed that 
L166P mutants still form homodimers in vitro albeit with reduced efficiency and have a 
higher tendency of forming oligomers of higher molecular weight than wild-type DJ-1. 
 
7.3 DJ-1 as a Cysteine Protease 
Observations that DJ-1 possessed a putative catalytic diad, made up of Cys-106 and His-126 
which could function in a manner similar to the Cys-His-Glu/Asp catalytic triad characteristic 
of well-characterised aspartate proteases led to proposals that DJ-1 might function as a 
protease. Olzmann and coworkers (119) demonstrated DJ-1 protease activity using a highly 
sensitive, fluorescence-based protease assay, which led to the conclusion that DJ-1 possesses 
a weak intrinsic protease activity that required activation, a view shared by Chen and 
coworkers (101), who proved that 15 amino acids of the C-terminal helix, α8, of DJ-1 are 
cleaved to convert the zymogen into an active protease. Apoptosis assays confirmed that the 
expression of C-terminally cleaved wild-type DJ-1 in cells results in increased 
neuroprotection compared to wild-type DJ-1. A likely explanation for this is that α8 obscures 
substrate access to the active site pocket. The cleavage might also allow the imidazole side 
chain of His 126 to orient properly to complete a catalytic diad with Cys106. The substrate 
specificity of DJ-1 has not been determined and the only known potential sites of cleavage are 
at the peptide bonds: Gly-Pro and Gly-Lys. 
In view of the importance of the L166P mutation for dimerization and the requirement of C-
terminal helix deletion for DJ-1 protease activity, I cloned and expressed two mutants of DJ-1 
for further investigation into the effects of these variants of DJ-1 on its interaction with G-
substrate. 
Using wild type DJ-1 clones kindly provided by Dr. Mark A. Wilson (University of 
Nebraska) site-directed mutagenesis of leucine 166 to proline was carried out by PCR with 
the oligonucleotide primers: 
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5‟ GC AGG CGC AAA CTC GAA GC 3‟ and  
5‟CG CCT GCA ATT GTT GAA GCC C 3‟. 
A second DJ-1 mutant with site directed mutagenesis of the lysine at position 175 to a stop 
codon (K175Stop), which mimicks the activated form of DJ-1 by removal of the C-terminal 
alpha-helix (see section 7.2 above) by PCR using the oligonucleotide primers: 5‟ GC CGC 
CAC CTC CTA GCC 3‟ and  
5‟GCC CTG AAT GGC TAG GAG G 3‟.  
Functional analysis of the mtuants was carried out in collaboration with three project students: 
Sylvia Ispasanie (SI), Mun Ching Lee (MCL) and Sean McLaughlin-Stewart (SM-S). 
 
7.4 G-substrate as a DJ-1 substrate 
The observed interaction between G-substrate and DJ-1 is intriguing because both of these 
proteins have been linked to the protection of neuronal cells from toxins. Interestingly, both 
proteins have links to the pro-survival Akt pathway with DJ-1 promoting Akt phosphorylation 
upon exposure to oxidative stress (120) and phosphorylated G-substrate potently inhibiting 
PP2A, an important phospho-Akt phosphatase. Since the phosphorylation of Akt is necessary 
for its mediation of the pro survival pathway, it is possible that like DJ-1, G-substrate 
contributes to neuroprotection via the Akt signalling pathway and further investigation into 
the interaction of these two proteins in the light of this pro-survival pathway could yield vital 
information that could lead to valuable interventions for conditions such as PD and cancer. 
Due to this observation, the ability of DJ-1 to proteolyse both variants of human G-substrate 
was investigated in vitro in association with SI; DJ-1 protein activated by trypsin cleavage of 
its C-terminal tail was found to rapidly degrade both variants of G-substrate, with less rapid 
proteolysis observed for DJ-1 with an intact C-terminal tail (Figure 7.2). 
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Figure 7.2: Proteolysis of human G-substrate variants by wild type (WT DJ-1) and trypsin treated DJ-1. 
 
 
Given the importance of dimerization for the activity of DJ-1, the ability of the mutant L166P 
protein (which is thought to dimerise less well than the wild type protein) to degrade G-
substrate was investigated in association SM-S (Figure 7.4). Our results indicate that this 
mutant has minimal protease activity toward G-substrate possibly due to its inability to adopt 
the dimeric structure thought to be vital for proteolytic activity. 
We also analysed the second mutant, K175Stop, which lacks the 15 amino acid C-terminal 
section of wild type DJ-1 cleaved in the active protein for proteolytic activity toward G-
substrate.  
Although this variant displayed the expected constitutive proteolytic activity, this was shown 
to be significantly less (by approximately 32 %) than activated wild type DJ-1.  
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In unpublished work carried out in the Aitken laboratory, Tanganil (N-acetyl-DL-Leucine) 
pulled down DJ-1 from a rat brain preparation. This led to an investigation of its effects on 
DJ-1 action in vitro. Tanganil is a drug widely used to reduce the imbalance and autonomic 
symptoms associated with acute vertigo (15,121). Despite being used for over 40 years, its 
mode of action remains poorly understood. In animal models, Tanganil has been shown to 
accelerate vestibular compensation following unilateral labryrinthectomy (122,123). 
Vertigo is a condition of the vestibular system (see section 1.1.2.1) in which the subject 
experiences an erroneous perception of movement; either a feeling of movement when 
stationary or a false perception of the environment moving. The symptoms of vertigo are 
caused by a dysfunction of the vestibular nuclei or the inner ear canal (124). 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 7 –G-substrate, DJ-1 and Tanganil 136 
Vestibular compensation refers to the recovery of oculomotor and postural control after the 
loss of unilateral vestibular input either partially or completely (Curthoys, 1995). The 
symptoms observed following damage to unilateral vestibular inputs are characterized by the 
symptoms of acute vertigo, making the effectiveness of Tanganil at managing both conditions 
unsurprising. The interaction of the vestibular system is a key link between these two 
conditions and provides a logical neuronal system upon which the mechanism of Tanganil 
could be based. The vestibular system has been investigated as the potential target of Tanganil 
with the drug showing an effect on abnormally polarized medial vestibular neurons (15). 
 
 
7.4.2 Effect of Tanganil on G-substrate Degradation by DJ-1 
The effect of Tanganil on the degradation of G-substrate by DJ-1 was studied in association 
with SM-S by determining the time taken for DJ-1 to degrade G-substrate in the presence or 
absence of Tanganil. There was a significant reduction in proteolytic activity of activated wild 
type DJ-1, by about 30 % in the presence of Tanganil. The L166P variant showed minimal 
proteolytic activity, which was reduced slightly in the presences of Tanganil. No significant 
variation in proteolytic activity was observed for the K175Stop mutant in the presence of 
Tanganil (Figure 7.4). 
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Figure 7.4: Effect of Tanganil on the degradation of G-substrate by DJ-1 variants 
 
 
7.4.3 Effect of Tanganil on DJ-1 Dimerization 
Chemical cross-linking analysis performed in collaboration with MCL and SM-S using the 
crosslinker Bis [sulfosuccinimidyl] suberate (BS
3
) as described in „Materials and Methods‟, 
revealed that Tanganil increases dimeric levels of wild type DJ-1. The level of dimerization of 
wild type DJ-1 increased by 13 % (Figure 7.5), while dimerization of the L166P variant 
increased by 12 % - an indication that the presence of the drug affected wild type and L166P 
DJ-1 to approximately equal extents. In contrast, the extent of dimerization of the K175Stop 
variant remained unchanged at in the presence of Tanganil.  
The observation that Tanganil enhances the dimerization of the disease-causing L166P variant 
of DJ-1 presents the interesting prospect of exploiting this drug in attempts to resolve the 
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dimerization issues that are suspected to contribute to the PD pathology brought about by this 
mutation. This may contribute to the development of interventions for dealing with PD. 
 
 
Figure 7.5: Effect of Tanganil on the Dimerization of DJ-1 variants.  
Error bars represent the SEM of three replicates. 
 
 
The potential interaction between DJ-1 and G-substrate via the Akt signalling pathway and 
our observations that Tanganil contributes to the stability of dimeric DJ-1 and especially 
dimerization of the disease causing L166P mutant of this protein represents an important line 
of investigation towards the elucidation of molecular mechanisms that could be exploited in 
the alleviation of neurodegenerative events in the brain and nervous system.  
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7.5 Discussion 
Recent unpublished work in the Aitken laboratory has shown that N-acetyl-L-leucine is the 
active ingredient in Tanganil as far as affecting the interaction between DJ-1 and G-substrate 
is concerned. We have also shown that a number of other acetylated aliphatic L-amino acids 
including isoleucine, valine, lysine and norleucine also inhibit cleavage of G-substrate by DJ-
1. 
It is interesting that DJ-1, which is known to protect neurons from neurodegeneration due to 
oxidative stress successfully cleaves G-substrate, which is also known to be neuroprotective. 
One possibility is a role of DJ-1 in the regulation of G-substrate forms in the brain; 
phosphorylation activates the phosphatase inhibitory activity of the G-substrate isoforms and 
it is important that these phosphatase inhibitors are regulated in order that they do not persist 
beyond the time frame within which they are required. Recent work in the laboratory (data not 
shown) has revealed that DJ-1 cleaves phosphorylated G-substrate at a higher rate than the 
unphosphorylated forms, likely due to cleavage sites being more accessible as a result of the 
loss of structure in G-substrate that results from phosphorylation (discussed in sections 5.3 
and 5.4). This observation and the fact that wild type DJ-1 cleaves G-substrate more 
effectively than the less abundant mutant DJ-1 forms, further support a role for DJ-1 in the 
regulation of phosphatase inhibition by G-substrate in the brain. 
Observations that the presence of N-acetyl-L-leucine reduces the ability of DJ-1 to cleave G-
substrate (Figure 7.4) presents the possibility of selectively controlling the regulatory effect of 
DJ-1 on the phosphatase inhibitory activities of G-substrate. In cases like Alzheimer‟s 
diseases where it is believed that inhibition of PP2A contributes to the hyperphosphorylation 
of tau protein (125) which results in disease pathology, reducing the amounts of PP2A 
inhibitors including G-substrate present in the cell by processes such as cleavage of 
phosphorylated G-substrate by DJ-1 could result in an increase in the amount of PP2A 
available to dephosphorylate tau and potentially prevent hyperphosphorylation. In other 
instances where it is desirable to keep PP2A targets phosphorylated, the presence of N-acetyl-
L-Leucine might help achieve this purpose by reducing the efficacy of G-substrate cleavage 
by DJ-1, making more G-substrate available to inhibit phosphatase activity and keep the 
desired proteins in their phosphorylated states. 
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Figure 8.1: Summary of Main G-substrate Activities Discussed in this Work. 
*See Table 4.1 for a summary of the effects of different G-substrate forms on the activities of various 
phosphatases.
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8.1 General Discussion 
The short isoform of G-substrate was successfully cloned and expressed under conditions 
similar to those used for the full length protein. Both recombinant proteins were successfully 
phosphorylated in vitro under similar conditions. As expected, phosphorylation of the full 
length protein required approximately twice as much enzyme as the phosphorylation of short 
G-substrate to achieve similar rates of phosphorylation due to the short isoform possessing 
only half as many phosphorylation sites as full length G-substrate. 
I hypothesized that the phosphorylated short isoform of G-substrate would inhibit the 
phosphoprotein phosphatases PP1 and PP2A, both of which are known to be inhibited by the 
phosphorylated full length protein. This was expected due to the fact that phosphorylation of 
the threonine residue retained in the short isoform was determined to influence phosphatase 
inhibition more than the threonine residue absent from the short isoform. These experiments 
revealed that the short G-substrate isoform does inhibit phosphatase activity at levels similar 
to those of the full length protein, especially towards PP2A. Given the importance of PP2A in 
maintaining the balance between phosphorylation and dephosphorylation in cells, the ability 
of both isoforms to inhibit PP2A activity could be a strategy to ensure that it is possible to 
differentially regulate PP2A activity within cells using these two G-substrate isoforms. 
The activity of PP5 was most affected by the unphosphorylated full length protein, which 
reduced PP5 activity to approximately 70 % from the start of the experiment. The 
unphosphorylated short protein was not found to appreciably reduce PP5 activity. After about 
30 min, the effect of the phosphorylated full length protein on PP5 was very similar to the 
effects of the unphosphorylated forms of both isoforms and remained so throughout the time 
course. This observation suggests that the phosphorylated and unphosphorylated forms of the 
G-substrate isoforms might affect the different phosphatases they encounter in the cell in 
distinct ways, with the different forms inhibiting various phosphatases to different extents. As 
discussed in section 1.1, the various forms of G-substrate probably exist at different times or 
in distinct parts of the cell. Such a spatio-temporal distribution of the G-substrate forms might 
necessitate the specialization of the isoforms to regulate the relevant phosphatases effectively. 
Structure and Regulation of G-substrate in Neurodegenerative Disease 
Chapter 8 – General Discussion and Conclusions 142 
The analytical ultracentrifugation data agreed with predictions that the G-substrate protein 
existed as a monomer and formed no observable homodimers or oligomers. NMR 
spectroscopy results largely confirmed results from CD experiments indicating that in 
solution, both G-substrate isoforms possessed less than 10 % α helix structure, with the 
dominant secondary structure for both isoforms being loops and turns. This unstructured 
nature of G-substrate has been observed in other potent protein inhibitors of protein 
phosphatase 1, including Inhibitor-1, DARPP-32 and NIPP-1 and may be an indication that a 
substantial level of structural flexibility is required for optimum inhibition of protein 
phosphatase 1. Using CD, both G-substrate isoforms were also shown to recover their 
structures almost entirely after incubation at 85 °C. 
Prior to this study, very little information existed on the interaction of G-substrate with 
proteins apart from cGMP-dependent protein kinase, which phosphorylates G-substrate in 
vivo and protein phosphatases 1 and 2A. In addition, information available on G-substrate 
almost exclusively referred to the full length isoform, with barely any experimental data 
available for interactions involving the short isoform. 
Results obtained in this study revealed that the full length and short isoforms of G-substrate 
share interaction with proteins including myosin and the developmentally regulated brain 
protein drebrin. Since the amino acid sequence of the G-substrate peptide is identical to the 
phosphorylation motifs in both G-substrate isoforms, interactions with this peptide, most of 
which involve proteins functioning in the maintenance of cytoskeletal structure, can be 
attributed to the phosphorylated forms of both isoforms. Most of the unique interactions 
observed for the short isoform involved proteins associated with the cytoskeleton and cellular 
structure and included the motor protein dynamin and the F-actin-binding alpha-3 chain of 
tropomyosin. The full length protein interacted mainly with proteins involved with 
metabolism, ion transport and signalling. 
My results have also highlighted the possibility that G-substrate, through interaction with the 
IP3R1 protein, may provide a point of interaction between the cGMP/NO/PKG pathway and 
the inositol triphosphate pathway. 
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8.2 Conclusions 
Results from this study revealed G-substrate exists as a monomer with both isoforms existing 
in solution with over 70 % of their secondary structure classified as „unstructured‟. The full 
length protein however possessed about 1 % more α helix than the short isoform, making it 
slightly more compact in solution. 
Phosphorylated full length protein inhibits PP1 more potently than the other forms of G-
substrate under the conditions tested, while all the forms of G-substrate reduce the activity of 
PP2A to similar extents. In the case of PP5, the unphosphorylated full length protein was the 
most inhibitory form, while the unphosphorylated short protein had no effect on activity. 
The full length G-substrate protein interacted with a larger number of proteins than the short 
isoform. These proteins were mainly involved in cellular processes including metabolism, ion 
transport and signalling. The short isoform interacted with relatively few proteins, most of 
which were involved with the maintenance of cellular structure. The G-substrate peptide, 
representing phosphorylated forms of both isoforms, interacted with proteins associated with 
the cell cycle, cellular structure, transcription and translation. G-substrate also interacted with 
DJ-1, the protein associated with inheritable early onset Parkinson‟s disease type 7. In vitro 
experiments revealed that both isoforms of G-substrate were effectively proteolysed by 
activated DJ-1. The ability of DJ-1 to proteolyse the G-substrate isoforms was adversely 
affected by Tanganil, a drug used to treat vertigo and whose active form is N-acetyl-L-
leucine. 
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Chapter 9: Further Work 
Further investigation into G-substrate interacting proteins, including reciprocal pull-downs 
and western immunoblotting to confirm the interactions observed will provide much needed 
information about the role of G-substrate isoforms in the mammalian brain. 
The discovery that G-substrate protein is intrinsically disordered explains the lack of success 
with previous attempts at crystallizing the protein. Given that other inhibitors of PP1 although 
intrinsically disordered, acquire more structure upon binding to PP1 (discussed in section 5.5), 
it would be interesting to attempt to co-crystallize G-substrate and PP1 and elucidate the 
structure of G-substrate from the crystals obtained, since the structure of PP1 is known.  
It is also possible, after labelling with appropriate isotopes, to determine the structure of G-
substrate in solution, either by itself or bound to one of its interacting partners using nuclear 
magnetic resonance spectroscopy (NMR). Using this method, it is also possible to study the 
dynamics of the protein interactions and obtain further information on the mechanism of the 
interaction. Since interactions between kinases and their substrates are often transient, this 
would be an interesting way of studying the interaction between G-substrate and its kinase, 
the cyclic GMP-dependent protein kinase (PKG) since employing a method like 
crystallization would be potentially challenging due to the fact that kinases do not normally 
form stable complexes with their substrates. 
Further work is currently ongoing in the Aitken laboratory to study the interaction between 
DJ-1 and G-substrate and the effect of Tanganil on DJ-1. 
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Figure 11.1: Design of K175Stop mutant from wild type DJ-1.  
Point mutation is shown in red and primers are underlined. 
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Figure 11.2: Design of L166P mutant from wild type DJ-1.  
Point mutation is shown in red and primers are underlined. 
 
